OM protein - protein search, using sw model

Run on: April 22, 2003, 15:27:27 ; Search time 79 Seconds
(without alignments)
1688.403 Million cell updates/sec

Title: US-10-046-433-40
Perfect score: 1001
Sequence: 1 MAEPGHSHHLSARVRGRTER.....LGRSNHLPPRGLLMDLTQCR 1001

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 908470 seqs, 133250620 residues

Word size : 0

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 150 summaries

Database : A_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1001	100.0	1001	22	AAB35333	Human TR13 recepto
2	877	87.6	1013	21	AAB26179	Human CASB619 prot
3	708	70.7	1013	22	AAU12190	Human PRO4985 poly
4	704	70.3	750	22	AAB35328	Human TR13 recepto
5	675	67.4	1013	22	AAB83845	Amino acid sequenc
6	662	66.1	911	22	AAB83850	Amino acid sequenc
7	621	62.0	870	22	AAB83851	Amino acid sequenc
8	460	46.0	495	20	AAY59972	Human endometrium
9	249	24.9	383	22	AAB83853	Amino acid sequenc
10	216	21.6	372	22	AAB85768	Human seven-transm
11	150	15.0	208	21	AAB53442	Human colon cancer
12	147	14.7	147	22	AAB83849	Peptide fragment o
13	117	11.7	209	22	AAB83852	Amino acid sequenc
14	96	9.6	105	21	AAB26180	Human CASB619 prot
15	56	5.6	56	22	AAB83847	Peptide fragment o
16	52	5.2	52	22	AAB83848	Peptide fragment o
17	45	4.5	45	22	AAB83846	Peptide fragment o
18	38	3.8	150	20	AAY12274	Human 5' EST secre
19	21	2.1	1027	22	AAB70256	TR16-long receptor
20	15	1.5	411	22	AAB48372	Human SEC5 protein
21	15	1.5	464	22	AAB48377	Human SEC10 protei
22	15	1.5	963	22	AAB70255	TR16-short recepto
23	14	1.4	50	22	ABB39681	Peptide #7187 enco
24	14	1.4	50	22	ABB24346	Protein #6345 enco
25	14	1.4	50	22	AAM60397	Human brain expres
26	14	1.4	50	22	AAM73033	Human bone marrow
27	14	1.4	50	22	AAM19811	Peptide #6245 enco
28	14	1.4	50	22	AAM33257	Peptide #7294 enco
29	14	1.4	50	23	ABG42877	Human peptide enco
30	14	1.4	71	22	AAU21345	Human novel foetal
31	14	1.4	78	22	AAB70285	Peptide #29. Unid
32	10	1.0	10	21	AAB27114	Human CASB619 prot
33	10	1.0	10	21	AAB27115	Human CASB619 prot
34	10	1.0	10	21	AAB27116	Human CASB619 prot
35	10	1.0	10	21	AAB27117	Human CASB619 prot
36	10	1.0	10	21	AAB27118	Human CASB619 prot
37	10	1.0	10	21	AAB27119	Human CASB619 prot
38	10	1.0	10	21	AAB27120	Human CASB619 prot
39	10	1.0	10	21	AAB27121	Human CASB619 prot
40	10	1.0	10	21	AAB27122	Human CASB619 prot
41	10	1.0	10	21	AAB27123	Human CASB619 prot
42	10	1.0	10	21	AAB27124	Human CASB619 prot
43	10	1.0	10	21	AAB27125	Human CASB619 prot
44	10	1.0	10	21	AAB27126	Human CASB619 prot
45	10	1.0	10	21	AAB27128	Human CASB619 prot
46	10	1.0	10	21	AAB27129	Human CASB619 prot
47	10	1.0	10	21	AAB27130	Human CASB619 prot
48	10	1.0	10	21	AAB27131	Human CASB619 prot
49	10	1.0	10	21	AAB27132	Human CASB619 prot
50	10	1.0	10	21	AAB27133	Human CASB619 prot
51	10	1.0	10	21	AAB27134	Human CASB619 prot
52	10	1.0	10	21	AAB27135	Human CASB619 prot
53	10	1.0	10	21	AAB27136	Human CASB619 prot
54	10	1.0	10	21	AAB27137	Human CASB619 prot
55	10	1.0	10	21	AAB27138	Human CASB619 prot
56	10	1.0	10	21	AAB27139	Human CASB619 prot
57	10	1.0	10	21	AAB27140	Human CASB619 prot
58	10	1.0	10	21	AAB27141	Human CASB619 prot
59	9	0.9	9	21	AAB26181	Human CASB619 prot
60	9	0.9	9	21	AAB26182	Human CASB619 prot
61	9	0.9	9	21	AAB26183	Human CASB619 prot
62	9	0.9	9	21	AAB26184	Human CASB619 prot
63	9	0.9	9	21	AAB26185	Human CASB619 prot
64	9	0.9	9	21	AAB26186	Human CASB619 prot
65	9	0.9	9	21	AAB26187	Human CASB619 prot
66	9	0.9	9	21	AAB26188	Human CASB619 prot
67	9	0.9	9	21	AAB26190	Human CASB619 prot
68	9	0.9	9	21	AAB26191	Human CASB619 prot
69	9	0.9	9	21	AAB26192	Human CASB619 prot
70	9	0.9	9	21	AAB26193	Human CASB619 prot
71	9	0.9	9	21	AAB26194	Human CASB619 prot
72	9	0.9	9	21	AAB26195	Human CASB619 prot
73	9	0.9	9	21	AAB26196	Human CASB619 prot
74	9	0.9	9	21	AAB26197	Human CASB619 prot
75	9	0.9	9	21	AAB26199	Human CASB619 prot
76	9	0.9	9	21	AAB26200	Human CASB619 prot
77	9	0.9	9	21	AAB26201	Human CASB619 prot
78	9	0.9	9	21	AAB26202	Human CASB619 prot
79	9	0.9	9	21	AAB27101	Human CASB619 prot
80	9	0.9	9	21	AAB27102	Human CASB619 prot
81	9	0.9	9	21	AAB27103	Human CASB619 prot
82	9	0.9	9	21	AAB27104	Human CASB619 prot
83	9	0.9	9	21	AAB27105	Human CASB619 prot

84	9	0.9	9	21	AAB27106	Human CASB619 prot
85	9	0.9	9	21	AAB27107	Human CASB619 prot
86	9	0.9	9	21	AAB27108	Human CASB619 prot
87	9	0.9	9	21	AAB27109	Human CASB619 prot
88	9	0.9	9	21	AAB27110	Human CASB619 prot
89	9	0.9	9	21	AAB27111	Human CASB619 prot
90	9	0.9	9	21	AAB27112	Human CASB619 prot
91	9	0.9	9	21	AAB27142	Human CASB619 prot
92	9	0.9	32	22	ABB38903	Peptide #6409 enco
93	9	0.9	32	22	ABB23896	Protein #5895 enco
94	9	0.9	32	22	AAM59554	Human brain expres
95	9	0.9	32	22	AAM72123	Human bone marrow
96	9	0.9	32	22	AAM19447	Peptide #5881 enco
97	9	0.9	32	22	AAM32385	Peptide #6422 enco
98	9	0.9	32	23	ABG41937	Human peptide enco
99	9	0.9	519	21	AAB57102	Human prostate can
100	9	0.9	748	22	AAM78689	Human protein SEQ
101	9	0.9	748	22	AAM93937	Human polypeptide,
102	8	0.8	8	22	AAB70277	Peptide #21. Unid
103	8	0.8	27	21	AAY78753	Hypervariable regi
104	8	0.8	27	23	AAE18094	Biotinylated hepat
105	8	0.8	60	22	ABB38686	Peptide #6192 enco
106	8	0.8	60	22	ABB23759	Protein #5758 enco
107	8	0.8	60	22	AAM59318	Human brain expres
108	8	0.8	60	22	AAM71867	Human bone marrow
109	8	0.8	60	22	AAM32149	Peptide #6186 enco
110	8	0.8	60	23	ABG41680	Human peptide enco
111	8	0.8	64	22	AAM72925	Human bone marrow
112	8	0.8	64	23	ABG42760	Human peptide enco
113	8	0.8	74	22	AAB70281	Peptide #25. Unid
114	8	0.8	120	22	AAU50366	Propionibacterium
115	8	0.8	241	21	AAG27726	Arabidopsis thalia
116	8	0.8	241	21	AAG44479	Arabidopsis thalia
117	8	0.8	241	21	AAG54122	Arabidopsis thalia
118	8	0.8	241	21	AAG54125	Arabidopsis thalia
119	8	0.8	308	9	AAP81167	Horseradish peroxi
120	8	0.8	308	10	AAP94810	Sequence of horser
121	8	0.8	309	10	AAP95200	Horseradish peroxi
122	8	0.8	309	21	AAY45051	Horseradish peroxi
123	8	0.8	309	21	AAY45052	Horseradish peroxi
124	8	0.8	309	21	AAY45053	Horseradish peroxi
125	8	0.8	309	21	AAY45054	Horseradish peroxi
126	8	0.8	309	21	AAY45055	Horseradish peroxi
127	8	0.8	309	21	AAY45056	Horseradish peroxi
128	8	0.8	309	21	AAY45057	Horseradish peroxi
129	8	0.8	309	21	AAY45058	Horseradish peroxi
130	8	0.8	309	21	AAY45059	Horseradish peroxi
131	8	0.8	309	21	AAY45060	Horseradish peroxi
132	8	0.8	309	21	AAY32291	Horseradish peroxi
133	8	0.8	309	22	AAG79250	Amino acid sequenc
134	8	0.8	309	22	AAG79251	Amino acid sequenc
135	8	0.8	309	22	AAG79252	Amino acid sequenc
136	8	0.8	309	22	AAG79253	Amino acid sequenc
137	8	0.8	309	22	AAG79254	Amino acid sequenc
138	8	0.8	309	22	AAG79255	Amino acid sequenc
139	8	0.8	309	22	AAG79256	Amino acid sequenc
140	8	0.8	309	22	AAG79257	Amino acid sequenc
141	8	0.8	309	22	AAG79258	Amino acid sequenc
142	8	0.8	309	22	AAG79259	Amino acid sequenc
143	8	0.8	309	23	ABB08125	Recombinant horser
144	8	0.8	332	21	AAG27725	Arabidopsis thalia
145	8	0.8	332	21	AAG44478	Arabidopsis thalia
146	8	0.8	332	21	AAG54121	Arabidopsis thalia
147	8	0.8	332	21	AAG54124	Arabidopsis thalia
148	8	0.8	342	10	AAP95203	Horseradish peroxi
149	8	0.8	349	14	AAR32760	HRP/IGF-II fusion
150	8	0.8	353	21	AAG44477	Arabidopsis thalia

ALIGNMENTS

RESULT 1

AAB35333
ID AAB35333 standard; Protein; 1001 AA.
XX
AC AAB35333;
XX
DT 08-MAY-2001 (first entry)
XX
DE Human TR13 receptor protein SEQ ID NO: 40.
XX
KW Human; tumour necrosis factor receptor; TR13; TR14; infection;
KW cancer; autoimmune disease; allergy; inflammatory disease;
KW graft rejection; apoptosis; cardiovascular disease; aneurysm.
XX
OS Homo sapiens.
XX
PN WO200105834-A1.
XX
PD 25-JAN-2001.
XX
PF 14-JUL-2000; 2000WO-US19343.
XX
PR 16-JUL-1999; 99US-0144087.
PR 18-AUG-1999; 99US-0149450.
PR 20-AUG-1999; 99US-0149712.
PR 10-SEP-1999; 99US-0153089.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Ni J, Young PE;
XX
DR WPI; 2001-112682/12.
XX
PT Nucleic acids encoding 2 human tumor necrosis factor receptor
PT polypeptides ((TR13) and (TR14)), useful for the prevention, diagnosis
PT and treatment of, e.g. cancers, acquired immune deficiency syndrome and
PT hypohidrotic ectodermal dysplasia -
XX
PS Claim 40; Page 398-401; 418pp; English.
XX
CC The present invention provides the protein and coding sequences of the
CC human tumour necrosis factor receptors TR13 and TR14. These sequences are
CC useful in the diagnosis and treatment of many diseases, including cancer,
CC autoimmune diseases, cardiovascular disorders, allergies,
CC neurodegenerative diseases, graft rejection, inflammation, aneurysms and
CC infections.
XX
SQ Sequence 1001 AA;

Query Match 100.0%; Score 1001; DB 22; Length 1001;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1001; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60

Qy      61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120

Qy     121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIAFNTDECTATLMYA 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIAFNTDECTATLMYA 180

Qy     181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240

Qy     241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300

Qy     301 SNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKIC 360
```

```
Db    301 SNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKIC 360

Qy    361 SEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEPAVG 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    361 SEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEPAVG 420

Qy    421 FEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFR 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    421 FEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFR 480

Qy    481 PPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYI 540
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    481 PPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYI 540

Qy    541 IEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGS 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    541 IEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGS 600

Qy    601 SCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTF 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    601 SCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTF 660

Qy    661 SRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTD 720
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    661 SRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTD 720

Qy    721 LRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGITS 780
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    721 LRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGITS 780

Qy    781 PAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDGT 840
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    781 PAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDGT 840

Qy    841 CDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRVT 900
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    841 CDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRVT 900

Qy    901 ICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPAADS 960
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    901 ICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPAADS 960

Qy    961 CAIMEGEDVEDDLIFTSKNHSLGRSNHLPPRGLLMDLTQCR 1001
          |||||||||||||||||||||||||||||||||||||||||
Db    961 CAIMEGEDVEDDLIFTSKNHSLGRSNHLPPRGLLMDLTQCR 1001
```

RESULT 2
AAB26179
ID AAB26179 standard; Protein; 1013 AA.
XX
AC AAB26179;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein #1.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
DR N-PSDB; AAA95442.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Claim 4; Page 54-56; 68pp; English.
XX
CC The present sequence comprises the human CASB619 protein sequence. This
CC protein is thought to be specifically or over-expressed in tumour cells,
CC and so can be used as a target for antigen-specific immune responses
CC which can cause destruction of the tumour cell. In addition, the protein
CC and gene can be used in cancer diagnosis, in the treatment of autoimmune
CC diseases and in vaccines against cancer and autoimmune disease. The
CC invention provides a number of epitopes derived from the protein which
CC can be used as immunogens.
XX
SQ Sequence 1013 AA;

Query Match 87.6%; Score 877; DB 21; Length 1013;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 977; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy      1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60

Qy     61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120

Qy    121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIAFNTDECTATLMYA 180
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIASNTDECTATLMYA 180

Qy    181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240

Qy    241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300

Qy    301 SNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKIC 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    301 SNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKIC 360

Qy    361 SEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEPAVG 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    361 SEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEPAVG 420

Qy    421 FEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFR 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    421 FEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFR 480

Qy    481 PPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYI 540
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    481 PPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYI 540

Qy    541 IEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGS 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    541 IEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGS 600

Qy    601 SCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTF 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    601 SCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTF 660

Qy    661 SRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTD 720
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db    661 SRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTD 720

Qy    721 LRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGITS 780
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    721 LRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGITS 780

Qy    781 PAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDGT 840
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    781 PAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDGT 840

Qy    841 CDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRVT 900
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    841 CDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRVT 900

Qy    901 ICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPAADS 960
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    901 ICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPAADS 960

Qy    961 CAIMEGEDVEDDLIFTSK 978
          ||||||||||||||||||
Db    961 CAIMEGEDVEDDLIFTSK 978


RESULT 3
AAU12190
ID   AAU12190 standard; Protein; 1013 AA.
XX
AC   AAU12190;
XX
DT   24-OCT-2001  (first entry)
XX
DE   Human PRO4985 polypeptide sequence.
XX
KW   Human secretory and transmembrane; PRO; mammalian; cancer; lung;
KW   breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha;
KW   cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle;
KW   adipocyte; A-peptide; factor VIIA; gene therapy.
XX
OS   Homo sapiens.
XX
PN   WO200140466-A2.
XX
PD   07-JUN-2001.
XX
PF   01-DEC-2000; 2000WO-US32678.
XX
PR   01-DEC-1999;   99WO-US28301.
PR   01-DEC-1999;   99WO-US28634.
PR   02-DEC-1999;   99WO-US28551.
PR   02-DEC-1999;   99WO-US28564.
PR   02-DEC-1999;   99WO-US28565.
PR   09-DEC-1999;   99US-0170262.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   20-DEC-1999;   99WO-US30999.
PR   30-DEC-1999;   99WO-US31243.
PR   06-JAN-2000; 2000WO-US00277.
PR   06-JAN-2000; 2000WO-US00376.
PR   11-FEB-2000; 2000WO-US03565.
PR   18-FEB-2000; 2000WO-US04341.
PR   18-FEB-2000; 2000WO-US04342.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US04914.
PR   24-FEB-2000; 2000WO-US05004.
PR   01-MAR-2000; 2000WO-US05601.
PR   20-MAR-2000; 2000WO-US07377.
PR   21-MAR-2000; 2000WO-US07532.
PR   30-MAR-2000; 2000WO-US08439.
PR   17-MAY-2000; 2000WO-US13705.
PR   22-MAY-2000; 2000WO-US14042.
PR   30-MAY-2000; 2000WO-US14941.
PR   02-JUN-2000; 2000WO-US15264.
PR   10-NOV-2000; 2000WO-US30873.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2001-408281/43.
DR   N-PSDB; AAS21262.
XX
PT   Isolated, secretory and transmembrane PRO polypeptide used to detect
PT   other PRO polypeptides, link bioactive molecules to cells expressing
PT   PRO polypeptides, and detect the presence of mammalian tumours e.g.
PT   lung, breast, prostate, cervical -
XX
PS   Claim 12; Fig 38; 813pp; English.
XX
CC   AAU12172-AAU12446 represent novel human secretory and transmembrane
CC   PRO polypeptides. The PRO polypeptides are useful to detect other
CC   PRO polypeptides, to link bioactive molecules to cells expressing
CC   PRO polypeptides, to modulate biological activities of cells expressing
CC   PRO polypeptides, and to detect the presence of mammalian lung, colon,
CC   breast, prostate, rectal, cervical or liver tumours by comparing PRO
CC   polypeptide expression in a cell sample to that in a control sample.
CC   Some of the 275 sequences are also useful to stimulate the release of
CC   tumour necrosis factor-alpha (TNF-alpha) from human blood, the
CC   proliferation or differentiation of chondrocytes, the proliferation or
CC   gene expression in pericyte cells, the release of proteoglycans from
CC   cartilage, the proliferation of inner ear utricular supporting cells or
CC   of T-lymphocytes, the release of a cytokine from peripheral blood
CC   monocytes (PBMCs), or the proliferation of endothelial cells. Some of
CC   the PRO polypeptides may modulate glucose or free fatty acid uptake by
CC   skeletal muscle cells or by adipocytes; or inhibit binding of A-peptide
CC   to factor VIIA. The PRO polypeptides can be used in assays to identify
CC   molecules involved in binding interactions. The polynucleotides encoding
CC   PRO polypeptides can be used to generate probes, antisense RNA/DNA,
CC   transgenic or knock out animals and can be used in gene therapy.
XX
SQ   Sequence   1013 AA;

  Query Match           70.7%;  Score 708;  DB 22;  Length 1013;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches  708;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    169 NTDECTATLMYAVNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGW 228
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    169 NTDECTATLMYAVNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGW 228

Qy    229 EFHSVELNRGNNVLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQG 288
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    229 EFHSVELNRGNNVLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQG 288

Qy    289 SSFCKLCPANSYSNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGET 348
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    289 SSFCKLCPANSYSNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGET 348

Qy    349 QLMYKWAKPKICSEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDC 408
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    349 QLMYKWAKPKICSEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDC 408

Qy    409 TRCPAGTEPAVGFEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDND 468
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    409 TRCPAGTEPAVGFEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDND 468

Qy    469 FMILTLVVPGFRPPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETW 528
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    469 FMILTLVVPGFRPPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETW 528

Qy    529 KGSKGKQSYTYIIEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYC 588
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    529 KGSKGKQSYTYIIEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYC 588

Qy    589 RPCALEASDVGSSCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNN 648
```

```
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    589 RPCALEASDVGSSCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNN 648

Qy    649 KIHSLCYNDCTFSRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQG 708
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    649 KIHSLCYNDCTFSRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQG 708

Qy    709 RKMSVCTDNVTDLRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIG 768
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    709 RKMSVCTDNVTDLRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIG 768

Qy    769 VTTDMTLDGITSPAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPG 828
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    769 VTTDMTLDGITSPAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPG 828

Qy    829 SLLLPGTCSDGTCDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQ 876
          ||||||||||||||||||||||||||||||||||||||||||||||||||
Db    829 SLLLPGTCSDGTCDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQ 876


RESULT 4
AAB35328
ID   AAB35328 standard; Protein; 750 AA.
XX
AC   AAB35328;
XX
DT   08-MAY-2001  (first entry)
XX
DE   Human TR13 receptor protein SEQ ID NO: 2.
XX
KW   Human; tumour necrosis factor receptor; TR13; TR14; infection;
KW   cancer; autoimmune disease; allergy; inflammatory disease;
KW   graft rejection; apoptosis; cardiovascular disease; aneurysm.
XX
OS   Homo sapiens.
XX
PN   WO200105834-A1.
XX
PD   25-JAN-2001.
XX
PF   14-JUL-2000; 2000WO-US19343.
XX
PR   16-JUL-1999;   99US-0144087.
PR   18-AUG-1999;   99US-0149450.
PR   20-AUG-1999;   99US-0149712.
PR   10-SEP-1999;   99US-0153089.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Ni J,  Young PE;
XX
DR   WPI; 2001-112682/12.
DR   N-PSDB; AAF27997.
XX
PT   Nucleic acids encoding 2 human tumor necrosis factor receptor
PT   polypeptides ((TR13) and (TR14)), useful for the prevention, diagnosis
PT   and treatment of, e.g. cancers, acquired immune deficiency syndrome and
PT   hypohidrotic ectodermal dysplasia -
XX
PS   Claim 40; Page 369-372; 418pp; English.
XX
CC   The present invention provides the protein and coding sequences of the
CC   human tumour necrosis factor receptors TR13 and TR14. These sequences are
CC   useful in the diagnosis and treatment of many diseases, including cancer,
CC   autoimmune diseases, cardiovascular disorders, allergies,
CC   neurodegenerative diseases, graft rejection, inflammation, aneurysms and
CC   infections.
XX
SQ   Sequence   750 AA;

  Query Match           70.3%;  Score 704;  DB 22;  Length 750;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches  704;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    298 NSYSNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKP 357
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     47 NSYSNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKP 106

Qy    358 KICSEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEP 417
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    107 KICSEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEP 166

Qy    418 AVGFEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVP 477
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    167 AVGFEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVP 226

Qy    478 GFRPPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSY 537
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    227 GFRPPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSY 286

Qy    538 TYIIEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASD 597
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    287 TYIIEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASD 346

Qy    598 VGSSCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYND 657
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    347 VGSSCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYND 406

Qy    658 CTFSRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDN 717
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    407 CTFSRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDN 466

Qy    718 VTDLRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDG 777
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    467 VTDLRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDG 526

Qy    778 ITSPAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCS 837
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    527 ITSPAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCS 586

Qy    838 DGTCDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQ 897
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    587 DGTCDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQ 646

Qy    898 RVTICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPA 957
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    647 RVTICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPA 706

Qy    958 ADSCAIMEGEDVEDDLIFTSKNHSLGRSNHLPPRGLLMDLTQCR 1001
          |||||||||||||||||||||||||||||||||||||||||||||
Db    707 ADSCAIMEGEDVEDDLIFTSKNHSLGRSNHLPPRGLLMDLTQCR 750


RESULT 5
AAB83845
ID   AAB83845 standard; Protein; 1013 AA.
XX
AC   AAB83845;
XX
DT   23-JUL-2001  (first entry)
XX
DE   Amino acid sequence of a human protein expressed in tumour cells.
XX
KW   Tumour cell; immunological disease; autoimmune disease; cancer;
KW   infection.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..41
FT                   /note= "signal peptide"
FT   Domain          42..911
FT                   /note= "extracellular domain"
FT   Domain          912..930
FT                   /note= "transmembrane domain"
FT   Domain          931..1013
```

```
FT                   /note= "transmembrane domain"
XX
PN   WO200131003-A1.
XX
PD   03-MAY-2001.
XX
PF   30-OCT-2000; 2000WO-FR03032.
XX
PR   29-OCT-1999;   99FR-0013629.
XX
PA   (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
PI   Delneste Y,  Magistrelli G,  Jeannin P,  Bonnefoy J;
XX
DR   WPI; 2001-328651/34.
DR   N-PSDB; AAF89765.
XX
PT   New nucleic acid, expressed in tumours and lymphoid tissue is useful for
PT   identifying agents for treating tumours and autoimmune disease  -
XX
PS   Claim 9; Page 48-51; 85pp; French.
XX
CC   The present sequence represents a human protein expressed in tumour
CC   cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
CC   and for cloning isolated DNA; identifying mutant forms of the gene that
CC   encodes a human protein, where the mutations are associated with
CC   abnormal gene expression, or promoters and regulators of the gene,
CC   particularly for diagnosis; for recombinant expression of the derived
CC   protein; as probes and primers for detection and amplification; and
CC   as antisense therapeutics. The tumour expressed protein is useful for
CC   raising specific antibodies and to screen agents that modulate its
CC   activity, bind to it or interact with it. These agents are potentially
CC   useful for treatment or prevention of diseases associated with abnormal
CC   expression/activity of the protein, particularly immunological diseases
CC   (autoimmune diseases and cancer) or viral, bacterial, fungal or parasitic
CC   infections.
XX
SQ   Sequence   1013 AA;

  Query Match             67.4%;  Score 675;  DB 22;  Length 1013;
  Best Local Similarity   99.7%;  Pred. No. 0;
  Matches  975;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60

Qy      61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120

Qy     121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIAFNTDECTATLMYA 180
           |||||||||||||||||||||||||||||||||||||||||||| ||||||||||||
Db     121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIASNTDECTATLMYA 180

Qy     181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240

Qy     241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300

Qy     301 SNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKIC 360
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 SNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKIC 360

Qy     361 SEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEPAVG 420
           |||||||||||||||||||||||||||||||||||| ||||||||||||||||||||
Db     361 SEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGPYSNGSDCTRCPAGTEPAVG 420

Qy     421 FEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFR 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     421 FEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFR 480

Qy     481 PPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYI 540
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     481 PPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYI 540

Qy     541 IEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGS 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     541 IEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGS 600

Qy     601 SCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTF 660
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     601 SCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTF 660

Qy     661 SRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTD 720
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     661 SRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTD 720

Qy     721 LRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGITS 780
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     721 LRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGITS 780

Qy     781 PAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDGT 840
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     781 PAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDGT 840

Qy     841 CDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRVT 900
           |||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||
Db     841 CDGCNFHFLWESAAACPLCSVADYRAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRVT 900

Qy     901 ICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPAADS 960
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     901 ICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPAADS 960

Qy     961 CAIMEGEDVEDDLIFTSK 978
           ||||||||||||||||||
Db     961 CAIMEGEDVEDDLIFTSK 978


RESULT 6
AAB83850
ID   AAB83850 standard; Protein; 911 AA.
XX
AC   AAB83850;
XX
DT   23-JUL-2001  (first entry)
XX
DE   Amino acid sequence of a human protein expressed in tumour cells.
XX
KW   Tumour cell; immunological disease; autoimmune disease; cancer;
KW   infection.
XX
OS   Homo sapiens.
XX
PN   WO200131003-A1.
XX
PD   03-MAY-2001.
XX
PF   30-OCT-2000; 2000WO-FR03032.
XX
PR   29-OCT-1999;   99FR-0013629.
XX
PA   (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
PI   Delneste Y,  Magistrelli G,  Jeannin P,  Bonnefoy J;
XX
DR   WPI; 2001-328651/34.
DR   N-PSDB; AAF89774.
XX
PT   New nucleic acid, expressed in tumours and lymphoid tissue is useful for
PT   identifying agents for treating tumours and autoimmune disease  -
XX
PS   Claim 10; Page 60-63; 85pp; French.
```

```
XX
CC   The present sequence represents a human protein expressed in tumour
CC   cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
CC   and for cloning isolated DNA; identifying mutant forms of the gene that
CC   encodes a human protein, where the mutations are associated with
CC   abnormal gene expression, or promoters and regulators of the gene,
CC   particularly for diagnosis; for recombinant expression of the derived
CC   protein; as probes and primers for detection and amplification; and
CC   as antisense therapeutics. The tumour expressed protein is useful for
CC   raising specific antibodies and to screen agents that modulate its
CC   activity, bind to it or interact with it. These agents are potentially
CC   useful for treatment or prevention of diseases associated with abnormal
CC   expression/activity of the protein, particularly immunological diseases
CC   (autoimmune diseases and cancer) or viral, bacterial, fungal or parasitic
CC   infections.
XX
SQ   Sequence   911 AA;

  Query Match            66.1%;  Score 662;  DB 22;  Length 911;
  Best Local Similarity  99.8%;  Pred. No. 0;
  Matches  862;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60

Qy      61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120

Qy     121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIAFNTDECTATLMYA 180
           |||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||
Db     121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIASNTDECTATLMYA 180

Qy     181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240

Qy     241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300

Qy     301 SNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKIC 360
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 SNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKIC 360

Qy     361 SEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEPAVG 420
           |||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||
Db     361 SEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGPYSNGSDCTRCPAGTEPAVG 420

Qy     421 FEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFR 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     421 FEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFR 480

Qy     481 PPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYI 540
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     481 PPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYI 540

Qy     541 IEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGS 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     541 IEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGS 600

Qy     601 SCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTF 660
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     601 SCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTF 660

Qy     661 SRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTD 720
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     661 SRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTD 720

Qy     721 LRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGITS 780
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     721 LRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGITS 780

Qy     781 PAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDGT 840
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     781 PAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDGT 840

Qy     841 CDGCNFHFLWESAAACPLCSVADY 864
           ||||||||||||||||||||||||
Db     841 CDGCNFHFLWESAAACPLCSVADY 864


RESULT 7
AAB83851
ID   AAB83851 standard; Protein; 870 AA.
XX
AC   AAB83851;
XX
DT   23-JUL-2001  (first entry)
XX
DE   Amino acid sequence of a human protein expressed in tumour cells.
XX
KW   Tumour cell; immunological disease; autoimmune disease; cancer;
KW   infection.
XX
OS   Homo sapiens.
XX
PN   WO200131003-A1.
XX
PD   03-MAY-2001.
XX
PF   30-OCT-2000; 2000WO-FR03032.
XX
PR   29-OCT-1999;   99FR-0013629.
XX
PA   (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
PI   Delneste Y,  Magistrelli G,  Jeannin P,  Bonnefoy J;
XX
DR   WPI; 2001-328651/34.
DR   N-PSDB; AAF89775.
XX
PT   New nucleic acid, expressed in tumours and lymphoid tissue is useful for
PT   identifying agents for treating tumours and autoimmune disease  -
XX
PS   Claim 10; Page 67-70; 85pp; French.
XX
CC   The present sequence represents a human protein expressed in tumour
CC   cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
CC   and for cloning isolated DNA; identifying mutant forms of the gene that
CC   encodes a human protein, where the mutations are associated with
CC   abnormal gene expression, or promoters and regulators of the gene,
CC   particularly for diagnosis; for recombinant expression of the derived
CC   protein; as probes and primers for detection and amplification; and
CC   as antisense therapeutics. The tumour expressed protein is useful for
CC   raising specific antibodies and to screen agents that modulate its
CC   activity, bind to it or interact with it. These agents are potentially
CC   useful for treatment or prevention of diseases associated with abnormal
CC   expression/activity of the protein, particularly immunological diseases
CC   (autoimmune diseases and cancer) or viral, bacterial, fungal or parasitic
CC   infections.
XX
SQ   Sequence   870 AA;

  Query Match            62.0%;  Score 621;  DB 22;  Length 870;
  Best Local Similarity  99.8%;  Pred. No. 0;
  Matches  821;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy      42 TGPELHACKESEYHYEYTACDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFL 101
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 TGPELHACKESEYHYEYTACDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFL 60

Qy     102 DMKDQSCKPCAEGRYSLGTGIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVP 161
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 DMKDQSCKPCAEGRYSLGTGIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVP 120
```

```
Qy    162 RGDYIAFNTDECTATLMYAVNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWM 221
          ||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 RGDYIASNTDECTATLMYAVNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWM 180

Qy    222 KTTEKGWEFHSVELNRGNNVLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPG 281
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 KTTEKGWEFHSVELNRGNNVLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPG 240

Qy    282 TYADKQGSSFCKLCPANSYSNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTA 341
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    241 TYADKQGSSFCKLCPANSYSNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTA 300

Qy    342 CDANGETQLMYKWAKPKICSEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGS 401
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    301 CDANGETQLMYKWAKPKICSEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGP 360

Qy    402 YSNGSDCTRCPAGTEPAVGFEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTA 461
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    361 YSNGSDCTRCPAGTEPAVGFEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTA 420

Qy    462 AGASDNDFMILTLVVPGFRPPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRT 521
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    421 AGASDNDFMILTLVVPGFRPPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRT 480

Qy    522 NTPVETWKGSKGKQSYTYIIEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVM 581
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    481 NTPVETWKGSKGKQSYTYIIEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVM 540

Qy    582 NGVASYCRPCALEASDVGSSCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPC 641
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    541 NGVASYCRPCALEASDVGSSCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPC 600

Qy    642 GPGTKNNKIHSLCYNDCTFSRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTL 701
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    601 GPGTKNNKIHSLCYNDCTFSRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTL 660

Qy    702 SLCGNQGRKMSVCTDNVTDLRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVS 761
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    661 SLCGNQGRKMSVCTDNVTDLRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVS 720

Qy    762 LADRLIGVTTDMTLDGITSPAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCS 821
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    721 LADRLIGVTTDMTLDGITSPAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCS 780

Qy    822 PQKTVPGSLLLPGTCSDGTCDGCNFHFLWESAAACPLCSVADY 864
          |||||||||||||||||||||||||||||||||||||||||||
Db    781 PQKTVPGSLLLPGTCSDGTCDGCNFHFLWESAAACPLCSVADY 823
```

RESULT 8
AAY59972
ID AAY59972 standard; Protein; 495 AA.
XX
AC AAY59972;
XX
DT 31-JAN-2000 (first entry)
XX
DE Human endometrium tumour EST encoded protein 32.
XX
KW Endometrium; human; tumour; cancer; anticancer; cytostatic; EST:
KW treatment; uterine; gene therapy; expressed sequence tag.
XX
OS Homo sapiens.
XX
PN DE19817948-A1.
XX
PD 21-OCT-1999.
XX
PF 17-APR-1998; 98DE-1017948.
XX
PR 17-APR-1998; 98DE-1017948.
XX
PA (META-) METAGEN GES GENOMFORSCHUNG MBH.
XX
PI Rosenthal A, Specht T, Hinzmann B, Schmitt A, Pilarsky C, Dahl E;
XX
DR WPI; 1999-591957/51.
DR N-PSDB; AAZ41991.
XX
PT New nucleic acid sequences expressed in uterine cancer tissues, and
PT derived polypeptides, for treatment of uterine and endometrial cancer
PT and identification of therapeutic agents -
XX
PS Claim 23; Page 287; 444pp; German.
XX
CC This invention describes novel human nucleic acid (cDNA) sequences (A),
CC that are highly expressed in uterine tumour tissue and which have
CC anticancer and cytostatic activity. (A) are used (i) for recombinant
CC expression of polypeptides (B) and (ii) to isolate complete genes. (B)
CC are used (i) to identify agents suitable for treatment of uterine or
CC endometrial cancer; (ii) directly for treating these forms of cancer
CC (including expression from gene therapy vectors) and (iii) for
CC generation of specific antibodies. (A) are identified by assembling ESTs
CC (expressed sequence tags) from a particular tissue type before comparison
CC of expression patterns. This allows a significantly longer fragment of
CC the gene to be revealed, so should reduce the number of failures
CC associated with the fact that ESTs from different libraries may represent
CC different parts of the same unknown gene, distorting the estimated
CC frequency of occurrence in a particular tissue. AAY59941-Y60328 represent
CC protein fragments encoded by the human endometrium tumour cDNA library
CC derived EST fragments represented in AAZ41981-Z42121.
XX
SQ Sequence 495 AA;

```
  Query Match             46.0%;  Score 460;  DB 20;  Length 495;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches  460;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    519 SRTNTPVETWKGSKGKQSYTYIIEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVT 578
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 SRTNTPVETWKGSKGKQSYTYIIEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVT 60

Qy    579 NVMNGVASYCRPCALEASDVGSSCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQAC 638
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 NVMNGVASYCRPCALEASDVGSSCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQAC 120

Qy    639 VPCGPGTKNNKIHSLCYNDCTFSRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHH 698
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 VPCGPGTKNNKIHSLCYNDCTFSRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHH 180

Qy    699 FTLSLCGNQGRKMSVCTDNVTDLRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQ 758
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 FTLSLCGNQGRKMSVCTDNVTDLRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQ 240

Qy    759 PVSLADRLIGVTTDMTLDGITSPAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRV 818
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    241 PVSLADRLIGVTTDMTLDGITSPAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRV 300

Qy    819 RCSPQKTVPGSLLLPGTCSDGTCDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKT 878
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    301 RCSPQKTVPGSLLLPGTCSDGTCDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKT 360

Qy    879 TYVWREPKLCSGGISLPEQRVTICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLE 938
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    361 TYVWREPKLCSGGISLPEQRVTICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLE 420

Qy    939 YKYSKLVMNATLKDCDLPAADSCAIMEGEDVEDDLIFTSK 978
          |||||||||||||||||||||||||||||||||||||||||
Db    421 YKYSKLVMNATLKDCDLPAADSCAIMEGEDVEDDLIFTSK 460
```

RESULT 9
AAB83853
ID AAB83853 standard; Protein; 383 AA.
XX

```
AC   AAB83853;
XX
DT   23-JUL-2001  (first entry)
XX
DE   Amino acid sequence of a human protein expressed in tumour cells.
XX
KW   Tumour cell; immunological disease; autoimmune disease; cancer;
KW   infection.
XX
OS   Homo sapiens.
XX
PN   WO200131003-A1.
XX
PD   03-MAY-2001.
XX
PF   30-OCT-2000; 2000WO-FR03032.
XX
PR   29-OCT-1999;   99FR-0013629.
XX
PA   (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
PI   Delneste Y,  Magistrelli G,  Jeannin P,  Bonnefoy J;
XX
DR   WPI; 2001-328651/34.
DR   N-PSDB; AAF89777.
XX
PT   New nucleic acid, expressed in tumours and lymphoid tissue is useful for
PT   identifying agents for treating tumours and autoimmune disease  -
XX
PS   Claim 10; Page 74-75; 85pp; French.
XX
CC   The present sequence represents a human protein expressed in tumour
CC   cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
CC   and for cloning isolated DNA; identifying mutant forms of the gene that
CC   encodes a human protein, where the mutations are associated with
CC   abnormal gene expression, or promoters and regulators of the gene,
CC   particularly for diagnosis; for recombinant expression of the derived
CC   protein; as probes and primers for detection and amplification; and
CC   as antisense therapeutics. The tumour expressed protein is useful for
CC   raising specific antibodies and to screen agents that modulate its
CC   activity, bind to it or interact with it. These agents are potentially
CC   useful for treatment or prevention of diseases associated with abnormal
CC   expression/activity of the protein, particularly immunological diseases
CC   (autoimmune diseases and cancer) or viral, bacterial, fungal or parasitic
CC   infections.
XX
SQ   Sequence   383 AA;

  Query Match            24.9%;  Score 249;  DB 22;  Length 383;
  Best Local Similarity   99.7%;  Pred. No. 1.5e-253;
  Matches  349;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy     169 NTDECTATLMYAVNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGW 228
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      34 NTDECTATLMYAVNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGW 93

Qy     229 EFHSVELNRGNNVLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQG 288
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      94 EFHSVELNRGNNVLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQG 153

Qy     289 SSFCKLCPANSYSNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGET 348
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     154 SSFCKLCPANSYSNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGET 213

Qy     349 QLMYKWAKPKICSEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDC 408
           ||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||||
Db     214 QLMYKWAKPKICSEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGPYSNGSDC 273

Qy     409 TRCPAGTEPAVGFEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDND 468
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     274 TRCPAGTEPAVGFEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDND 333

Qy     469 FMILTLVVPGFRPPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVN 518
           |||||||||||||||||||||||||||||||||||||||||||||||||||
Db     334 FMILTLVVPGFRPPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVN 383


RESULT 10
AAB85768
ID   AAB85768 standard; Protein; 372 AA.
XX
AC   AAB85768;
XX
DT   29-OCT-2001  (first entry)
XX
DE   Human seven-transmembrane protein 50288 sequence.
XX
KW   seven-transmembrane protein; G-protein coupled receptor; GPCR; human;
KW   17724; 50288; 31945; antiinflammatory; antiulcer; cytostatic; virucide;
KW   hepatotropic; immunosuppressive; gynecological; neuroprotective;
KW   anti-HIV; immunostimulant; dermatological; antiatherosclerotic; cardiant;
KW   antianemic; antiParkinsonian; nephrotropic; antithyroid; hemostatic;
KW   cerebroprotective; osteopathic; analgesic; gene therapy; nootropic.
XX
OS   Homo sapiens.
XX
PN   WO200159117-A2.
XX
PD   16-AUG-2001.
XX
PF   12-FEB-2001; 2001WO-US04536.
XX
PR   11-FEB-2000; 2000US-0182061.
XX
PA   (MILL-) MILLENNIUM PHARM INC.
XX
PI   Glucksmann MA,  Silos-Santiago I;
XX
DR   WPI; 2001-514670/56.
DR   N-PSDB; AAH76195, AAH76196.
XX
PT   New seven-transmembrane protein/G-protein coupled receptor polypeptides
PT   and polynucleotides for diagnosing, treating seven-transmembrane
PT   protein/receptor-related disorders and to identify modulators of
PT   therapeutic use  -
XX
PS   Claim 8; Page 139-141; 144pp; English.
XX
CC   The invention provides isolated seven-transmembrane protein/G-protein
CC   coupled receptor polypeptides selected from 17724, 50288, 31945 proteins.
CC   The polypeptides can be expressed by standard recombinant methodology.
CC   Modulators of the polypeptides can be identified using a competition
CC   binding assay or an assay for receptor-mediated signal transduction. The
CC   polypeptides and polynucleotides are useful as reagents or targets in
CC   seven-transmembrane protein/receptor assays applicable to treatment and
CC   diagnosis of seven-transmembrane protein/receptor-mediated disorders
CC   (see AAH76191 for a detailed description of the various disorders that
CC   can be treated or diagnosed using the polypeptides). The polynucleotides
CC   are useful to detect mutations in genes and gene expression products such
CC   as mRNA, as antisense constructs to control gene expression and for
CC   chromosome identification. The present sequence represents the human
CC   seven transmembrane protein 50288 sequence.
XX
SQ   Sequence   372 AA;

  Query Match            21.6%;  Score 216;  DB 22;  Length 372;
  Best Local Similarity   99.7%;  Pred. No. 9.8e-219;
  Matches  316;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60

Qy      61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120
```

```
Qy    121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIAFNTDECTATLMYA 180
          ||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||
Db    121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIASNTDECTATLMYA 180

Qy    181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240

Qy    241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300

Qy    301 SNKGETSCHQCDPDKYS 317
          |||||||||||||||||
Db    301 SNKGETSCHQCDPDKYS 317
```

RESULT 11
AAB53442
ID AAB53442 standard; Protein; 208 AA.
XX
AC AAB53442;
XX
DT 09-MAR-2001 (first entry)
XX
DE Human colon cancer antigen protein sequence SEQ ID NO:982.
XX
KW Human; colon cancer; colon cancer antigen; diagnosis; detection;
KW identification; cytostatic; cardioactive; neuroprotective; vulnerary;
KW immunomodulatory; muscular; gynaecological; gastrointestinal;
KW nephrotropic; antiinfective; antibacterial; gene therapy; wound;
KW neural disorder; immune system disorder; muscular disorder;
KW reproductive disorder; gastrointestinal disorder; renal disorder;
KW infectious disease; cardiovascular disorder.
XX
OS Homo sapiens.
XX
PN WO200055351-A1.
XX
PD 21-SEP-2000.
XX
PF 08-MAR-2000; 2000WO-US05883.
XX
PR 12-MAR-1999; 99US-0124270.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM;
XX
DR WPI; 2000-587534/55.
DR N-PSDB; AAC98199.
XX
PT Colon cancer associated gene sequences, referred to as colon cancer
PT antigens, useful for the treatment, prevention, and diagnosis of colon
PT disorders such as colon cancer -
XX
PS Claim 11; Page 1556; 2104pp; English.
XX
CC AAC97991 to AAC98763 encode the human colon cancer associated proteins,
CC called human colon cancer antigens, given in AAB53234 to AAB54006. The
CC human colon cancer antigens can have cytostatic, cardioactive, muscular;
CC neuroprotective, immunomodulatory, gynaecological, gastrointestinal,
CC vulnerary, nephrotropic, antiinfective and antibacterial activities, and
CC can be used in gene therapy. The colon cancer antigen polynucleotides,
CC proteins and antibodies to the proteins are useful for the prevention,
CC treatment and diagnosis of colon disorders, such as colon cancer. The
CC polynucleotides may be used in diagnostics and research, such as for
CC chromosome identification, and as hybridisation probes. The proteins
CC may also be used to prevent diseases such as neural disorders, immune
CC system disorders, muscular disorders, reproductive disorders,
CC gastrointestinal disorders, wounds, renal disorders, infectious
CC diseases, and cardiovascular disorders. AAC98764 to AAC98772 and
CC AAB54007 represent sequences used in the exemplification of the present
CC invention.
XX
SQ Sequence 208 AA;

```
  Query Match             15.0%;  Score 150;  DB 21;  Length 208;
  Best Local Similarity   100.0%;  Pred. No. 2.7e-149;
  Matches  150;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    690 SKGLKYFHHFTLSLCGNQGRKMSVCTDNVTDLRIPEGESGFSKSITAYVCQAVIIPPEVT 749
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     30 SKGLKYFHHFTLSLCGNQGRKMSVCTDNVTDLRIPEGESGFSKSITAYVCQAVIIPPEVT 89

Qy    750 GYKAGVSSQPVSLADRLIGVTTDMTLDGITSPAELFHLESLGIPDVIFFYRSNDVTQSCS 809
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     90 GYKAGVSSQPVSLADRLIGVTTDMTLDGITSPAELFHLESLGIPDVIFFYRSNDVTQSCS 149

Qy    810 SGRSTTIRVRCSPQKTVPGSLLLPGTCSDG 839
          ||||||||||||||||||||||||||||||
Db    150 SGRSTTIRVRCSPQKTVPGSLLLPGTCSDG 179
```

RESULT 12
AAB83849
ID AAB83849 standard; peptide; 147 AA.
XX
AC AAB83849;
XX
DT 23-JUL-2001 (first entry)
XX
DE Peptide fragment of a human protein expressed in tumour cells.
XX
KW Tumour cell; immunological disease; autoimmune disease; cancer;
KW infection.
XX
OS Homo sapiens.
XX
PN WO200131003-A1.
XX
PD 03-MAY-2001.
XX
PF 30-OCT-2000; 2000WO-FR03032.
XX
PR 29-OCT-1999; 99FR-0013629.
XX
PA (FABR) FABRE MEDICAMENT SA PIERRE.
XX
PI Delneste Y, Magistrelli G, Jeannin P, Bonnefoy J;
XX
DR WPI; 2001-328651/34.
DR N-PSDB; AAF89769.
XX
PT New nucleic acid, expressed in tumours and lymphoid tissue is useful for
PT identifying agents for treating tumours and autoimmune disease -
XX
PS Claim 10; Page 54-55; 85pp; French.
XX
CC AAB83846-49 represent fragments of a human protein expressed in tumour
CC cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
CC and for cloning isolated DNA; identifying mutant forms of the gene that
CC encodes a human protein, where the mutations are associated with abnormal
CC gene expression, or promoters and regulators of the gene, particularly
CC for diagnosis; for recombinant expression of the derived protein; as
CC probes and primers for detection and amplification; and as antisense
CC therapeutics. The tumour expressed protein is useful for raising specific
CC antibodies and to screen agents that modulate its activity, bind to it
CC or interact with it. These agents are potentially useful for treatment
CC or prevention of diseases associated with abnormal expression/activity
CC of the protein, particularly immunological diseases (autoimmune diseases
CC and cancer) or viral, bacterial, fungal or parasitic infections.
XX
SQ Sequence 147 AA;

```
  Query Match             14.7%;  Score 147;  DB 22;  Length 147;
  Best Local Similarity   100.0%;  Pred. No. 2.9e-146;
  Matches  147;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     654 CYNDCTFSRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSV 713
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 CYNDCTFSRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSV 60

Qy     714 CTDNVTDLRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDM 773
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 CTDNVTDLRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDM 120

Qy     774 TLDGITSPAELFHLESLGIPDVIFFYR 800
           |||||||||||||||||||||||||||
Db     121 TLDGITSPAELFHLESLGIPDVIFFYR 147


RESULT 13
AAB83852
ID   AAB83852 standard; Protein; 209 AA.
XX
AC   AAB83852;
XX
DT   23-JUL-2001  (first entry)
XX
DE   Amino acid sequence of a human protein expressed in tumour cells.
XX
KW   Tumour cell; immunological disease; autoimmune disease; cancer;
KW   infection.
XX
OS   Homo sapiens.
XX
PN   WO200131003-A1.
XX
PD   03-MAY-2001.
XX
PF   30-OCT-2000; 2000WO-FR03032.
XX
PR   29-OCT-1999;   99FR-0013629.
XX
PA   (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
PI   Delneste Y,  Magistrelli G,  Jeannin P,  Bonnefoy J;
XX
DR   WPI; 2001-328651/34.
DR   N-PSDB; AAF89776.
XX
PT   New nucleic acid, expressed in tumours and lymphoid tissue is useful for
PT   identifying agents for treating tumours and autoimmune disease  -
XX
PS   Claim 10; Page 71-72; 85pp; French.
XX
CC   The present sequence represents a human protein expressed in tumour
CC   cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
CC   and for cloning isolated DNA; identifying mutant forms of the gene that
CC   encodes a human protein, where the mutations are associated with
CC   abnormal gene expression, or promoters and regulators of the gene,
CC   particularly for diagnosis; for recombinant expression of the derived
CC   protein; as probes and primers for detection and amplification; and
CC   as antisense therapeutics. The tumour expressed protein is useful for
CC   raising specific antibodies and to screen agents that modulate its
CC   activity, bind to it or interact with it. These agents are potentially
CC   useful for treatment or prevention of diseases associated with abnormal
CC   expression/activity of the protein, particularly immunological diseases
CC   (autoimmune diseases and cancer) or viral, bacterial, fungal or parasitic
CC   infections.
XX
SQ   Sequence   209 AA;

  Query Match             11.7%;  Score 117;  DB 22;  Length 209;
  Best Local Similarity   100.0%;  Pred. No. 1.8e-114;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     402 YSNGSDCTRCPAGTEPAVGFEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTA 461
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      93 YSNGSDCTRCPAGTEPAVGFEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTA 152

Qy     462 AGASDNDFMILTLVVPGFRPPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVN 518
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 AGASDNDFMILTLVVPGFRPPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVN 209


RESULT 14
AAB26180
ID   AAB26180 standard; Protein; 105 AA.
XX
AC   AAB26180;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein #2.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases  -
XX
PS   Disclosure; Page 56; 68pp; English.
XX
CC   The present sequence comprises part of the human CASB619 protein sequence
CC   derived from an EST. The CASB619 protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The invention provides a number of
CC   epitopes derived from the protein which can be used as immunogens.
XX
SQ   Sequence   105 AA;

  Query Match              9.6%;  Score 96;  DB 21;  Length 105;
  Best Local Similarity   100.0%;  Pred. No. 1.4e-92;
  Matches   96;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     864 YHAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRVTICKTIDFWLKVGISAGTCTAILL 923
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 YHAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRVTICKTIDFWLKVGISAGTCTAILL 60

Qy     924 TVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPAAD 959
           |||||||||||||||||||||||||||||||||||||
Db      61 TVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPAAD 96


RESULT 15
AAB83847
ID   AAB83847 standard; peptide; 56 AA.
XX
```

AC AAB83847;
XX
DT 23-JUL-2001 (first entry)
XX
DE Peptide fragment of a human protein expressed in tumour cells.
XX
KW Tumour cell; immunological disease; autoimmune disease; cancer;
KW infection.
XX
OS Homo sapiens.
XX
PN WO200131003-A1.
XX
PD 03-MAY-2001.
XX
PF 30-OCT-2000; 2000WO-FR03032.
XX
PR 29-OCT-1999; 99FR-0013629.
XX
PA (FABR) FABRE MEDICAMENT SA PIERRE.
XX
PI Delneste Y, Magistrelli G, Jeannin P, Bonnefoy J;
XX
DR WPI; 2001-328651/34.
DR N-PSDB; AAF89767.
XX
PT New nucleic acid, expressed in tumours and lymphoid tissue is useful for
PT identifying agents for treating tumours and autoimmune disease -
XX
PS Claim 10; Page 52-53; 85pp; French.
XX
CC AAB83846-49 represent fragments of a human protein expressed in tumour
CC cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
CC and for cloning isolated DNA; identifying mutant forms of the gene that
CC encodes a human protein, where the mutations are associated with abnormal
CC gene expression, or promoters and regulators of the gene, particularly
CC for diagnosis; for recombinant expression of the derived protein; as
CC probes and primers for detection and amplification; and as antisense
CC therapeutics. The tumour expressed protein is useful for raising specific
CC antibodies and to screen agents that modulate its activity, bind to it
CC or interact with it. These agents are potentially useful for treatment
CC or prevention of diseases associated with abnormal expression/activity
CC of the protein, particularly immunological diseases (autoimmune diseases
CC and cancer) or viral, bacterial, fungal or parasitic infections.
XX
SQ Sequence 56 AA;

Query Match 5.6%; Score 56; DB 22; Length 56;
Best Local Similarity 100.0%; Pred. No. 1.4e-50;
Matches 56; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 304 GETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKI 359
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 GETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKI 56

RESULT 16
AAB83848
ID AAB83848 standard; peptide; 52 AA.
XX
AC AAB83848;
XX
DT 23-JUL-2001 (first entry)
XX
DE Peptide fragment of a human protein expressed in tumour cells.
XX
KW Tumour cell; immunological disease; autoimmune disease; cancer;
KW infection.
XX
OS Homo sapiens.
XX
PN WO200131003-A1.
XX
PD 03-MAY-2001.
XX
PF 30-OCT-2000; 2000WO-FR03032.
XX
PR 29-OCT-1999; 99FR-0013629.
XX
PA (FABR) FABRE MEDICAMENT SA PIERRE.
XX
PI Delneste Y, Magistrelli G, Jeannin P, Bonnefoy J;
XX
DR WPI; 2001-328651/34.
DR N-PSDB; AAF89768.
XX
PT New nucleic acid, expressed in tumours and lymphoid tissue is useful for
PT identifying agents for treating tumours and autoimmune disease -
XX
PS Claim 10; Page 53; 85pp; French.
XX
CC AAB83846-49 represent fragments of a human protein expressed in tumour
CC cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
CC and for cloning isolated DNA; identifying mutant forms of the gene that
CC encodes a human protein, where the mutations are associated with abnormal
CC gene expression, or promoters and regulators of the gene, particularly
CC for diagnosis; for recombinant expression of the derived protein; as
CC probes and primers for detection and amplification; and as antisense
CC therapeutics. The tumour expressed protein is useful for raising specific
CC antibodies and to screen agents that modulate its activity, bind to it
CC or interact with it. These agents are potentially useful for treatment
CC or prevention of diseases associated with abnormal expression/activity
CC of the protein, particularly immunological diseases (autoimmune diseases
CC and cancer) or viral, bacterial, fungal or parasitic infections.
XX
SQ Sequence 52 AA;

Query Match 5.2%; Score 52; DB 22; Length 52;
Best Local Similarity 100.0%; Pred. No. 2.1e-46;
Matches 52; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 472 LTLVVPGFRPPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNT 523
||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 LTLVVPGFRPPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNT 52

RESULT 17
AAB83846
ID AAB83846 standard; peptide; 45 AA.
XX
AC AAB83846;
XX
DT 23-JUL-2001 (first entry)
XX
DE Peptide fragment of a human protein expressed in tumour cells.
XX
KW Tumour cell; immunological disease; autoimmune disease; cancer;
KW infection.
XX
OS Homo sapiens.
XX
PN WO200131003-A1.
XX
PD 03-MAY-2001.
XX
PF 30-OCT-2000; 2000WO-FR03032.
XX
PR 29-OCT-1999; 99FR-0013629.
XX
PA (FABR) FABRE MEDICAMENT SA PIERRE.
XX
PI Delneste Y, Magistrelli G, Jeannin P, Bonnefoy J;
XX
DR WPI; 2001-328651/34.
DR N-PSDB; AAF89766.
XX

```
PT   New nucleic acid, expressed in tumours and lymphoid tissue is useful for
PT   identifying agents for treating tumours and autoimmune disease -
XX
PS   Claim 10; Page 52; 85pp; French.
XX
CC   AAB83846-49 represent fragments of a human protein expressed in tumour
CC   cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
CC   and for cloning isolated DNA; identifying mutant forms of the gene that
CC   encodes a human protein, where the mutations are associated with abnormal
CC   gene expression, or promoters and regulators of the gene, particularly
CC   for diagnosis; for recombinant expression of the derived protein; as
CC   probes and primers for detection and amplification; and as antisense
CC   therapeutics. The tumour expressed protein is useful for raising specific
CC   antibodies and to screen agents that modulate its activity, bind to it
CC   or interact with it. These agents are potentially useful for treatment
CC   or prevention of diseases associated with abnormal expression/activity
CC   of the protein, particularly immunological diseases (autoimmune diseases
CC   and cancer) or viral, bacterial, fungal or parasitic infections.
XX
SQ   Sequence   45 AA;

  Query Match             4.5%;  Score 45;  DB 22;  Length 45;
  Best Local Similarity   100.0%;  Pred. No. 4.5e-39;
  Matches   45;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPE 45
          |||||||||||||||||||||||||||||||||||||||||||||
Db      1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPE 45


RESULT 18
AAY12274
ID   AAY12274 standard; Protein; 150 AA.
XX
AC   AAY12274;
XX
DT   17-JUN-1999  (first entry)
XX
DE   Human 5' EST secreted protein SEQ ID NO:305.
XX
KW   Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW   forensic; gene therapy; chromosome mapping; signal peptide;
KW   upstream regulatory sequence; cytokine activity; cell proliferation;
KW   differentiation; haematopoiesis regulation; tissue growth regulation;
KW   reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW   thrombolytic; anti-inflammatory; tumour inhibition.
XX
OS   Homo sapiens.
XX
PN   WO9906548-A2.
XX
PD   11-FEB-1999.
XX
PF   31-JUL-1998;   98WO-IB01222.
XX
PR   01-AUG-1997;   97US-0905135.
XX
PA   (GEST ) GENSET.
XX
PI   Duclert A,  Dumas Milne Edwards J,  Lacroix B;
XX
DR   WPI; 1999-153778/13.
DR   N-PSDB; AAX41107.
XX
PT   New nucleic acids encoding human secreted proteins - obtained from
PT   cDNA libraries prepared from e.g. liver, ovary, brain, prostate,
PT   kidney, lung, umbilical cord, placenta and colon tissue
XX
PS   Claim 27; Page 655-656; 824pp; English.
XX
CC   AAX41094 to AAX41347 represent 5' expressed sequence tags (ESTs) for
CC   human secreted proteins, and encode the proteins given in AAY12261 to
CC   AAY12514, respectively. The proteins given represent the signal peptide
CC   and an N-terminal fragment of a secreted protein. The nucleic acid
CC   sequences can be used for producing secreted human gene products. They
CC   can also be used to develop products for diagnosis and therapy. The
CC   proteins obtained may have cytokine activity, cell
CC   proliferation/differentiation activity, haematopoiesis regulating
CC   activity, tissue growth regulating activity, reproductive hormone
CC   regulating activity, chemotactic/ chemokinetic activity, haemostatic and
CC   thrombolytic activity, receptor/ ligand activity, anti-inflammatory
CC   activity, tumour inhibition activity or other activities. The products
CC   can be used in forensic, gene therapy and chromosome mapping procedures.
CC   The sequences can also be used for obtaining corresponding promoter
CC   sequences. The nucleic acids encoding the signal peptide can be used for
CC   directing extracellular secretion of a polypeptide or the insertion of a
CC   polypeptide into a membrane, or importing a polypeptide into a cell.
XX
SQ   Sequence   150 AA;

  Query Match             3.8%;  Score 38;  DB 20;  Length 150;
  Best Local Similarity   100.0%;  Pred. No. 3.3e-31;
  Matches   38;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQV 38
          |||||||||||||||||||||||||||||||||||||
Db      1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQV 38


RESULT 19
AAB70256
ID   AAB70256 standard; protein; 1027 AA.
XX
AC   AAB70256;
XX
DT   10-MAY-2001  (first entry)
XX
DE   TR16-long receptor protein.
XX
KW   TR16 recptor; tumour necrosis factor receptor superfamily;
KW   apoptosis; inflammatory; cancer; immune; neurodegenerative.
XX
OS   Unidentified.
XX
PN   WO200112671-A1.
XX
PD   22-FEB-2001.
XX
PF   10-AUG-2000; 2000WO-US21885.
XX
PR   12-AUG-1999;   99US-0148348.
PR   13-AUG-1999;   99US-0148683.
PR   13-AUG-1999;   99US-0148870.
PR   16-AUG-1999;   99US-0148758.
PR   17-AUG-1999;   99US-0149181.
PR   18-AUG-1999;   99US-0149453.
PR   19-AUG-1999;   99US-0149498.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Young PE,  Baker KP;
XX
DR   WPI; 2001-138754/14.
XX
PT   New nucleic acid molecule encoding a TR16 tumor necrosis factor
PT   receptor polypeptide, useful for the diagnosis and treatment of cancer,
PT   autoimmune disorders and cardiovascular diseases -
XX
PS   Disclosure; Fig 4; 286pp; English.
XX
CC   The present invention relates to a TR16 receptor (tumour necrosis
CC   factor receptor superfamily). The invention is useful treating
CC   diseases and disorders associated with the inhibited or increased
CC   apoptosis. In particular inflammatory diseases, cancers, immune and
CC   neurodegenerative disorders may be treated.
XX
```

```
SQ   Sequence   1027 AA;

  Query Match             2.1%;  Score 21;  DB 22;  Length 1027;
  Best Local Similarity   100.0%;  Pred. No. 1.6e-12;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    926 LTCYFWKKNQKLEYKYSKLVM 946
          |||||||||||||||||||||
Db    943 LTCYFWKKNQKLEYKYSKLVM 963


RESULT 20
AAB48372
ID   AAB48372 standard; Protein; 411 AA.
XX
AC   AAB48372;
XX
DT   20-APR-2001  (first entry)
XX
DE   Human SEC5 protein sequence (clone ID 1795045.0.61).
XX
KW   SECX; cytostatic; gynecological; gene therapy; screening assay; human;
KW   SEC5; chromosomal mapping; forensic biology; cell proliferation; cancer;
KW   cell differentiation; immune associated disorder; gestational disease.
XX
OS   Homo sapiens.
XX
PN   WO200078802-A2.
XX
PD   28-DEC-2000.
XX
PF   23-JUN-2000; 2000WO-US17328.
XX
PR   23-JUN-1999;   99US-0140584.
PR   20-JUL-1999;   99US-0144722.
PR   16-SEP-1999;   99US-0154520.
PR   22-JUN-2000; 2000US-0604286.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Shimkets RA,  Fernandes E,  Vernet C,  Yang M,  Boldog FL;
PI   Herrmann JL;
XX
DR   WPI; 2001-071385/08.
DR   N-PSDB; AAC84886.
XX
PT   Polynucleotides encoding SECX proteins useful for treating disease
PT   characterized by an aberrant level of cell proliferation and/or
PT   differentiation like cancer or immune associated disorders -
XX
PS   Claim 1; Fig 6; 132pp; English.
XX
CC   The invention relates to human SECX polypeptides and polynucleotides
CC   encoding them. The SECX polypeptides can be expressed by standard
CC   recombinant methodology.  The SECX polypeptides are useful for treating
CC   or preventing a SECX-associated disorder. The invention is useful in
CC   screening assays; detection assays (e.g. chromosomal mapping, cell and
CC   tissue typing, forensic biology); predictive medicine (diagnostic assays,
CC   prognostic assays, monitoring clinical trials, and pharmocogenomics); and
CC   methods of treatment (e.g. therapeutic and prophylactic), especially
CC   disorders characterized by aberrant cell proliferation and/ or
CC   differentiation like cancer or immune associated disorders or gestational
CC   disease. The present sequence represents a SEC5 protein.
XX
SQ   Sequence   411 AA;

  Query Match             1.5%;  Score 15;  DB 22;  Length 411;
  Best Local Similarity   100.0%;  Pred. No. 1.5e-06;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    268 GVAYTSECFPCKPGT 282
          |||||||||||||||
Db    116 GVAYTSECFPCKPGT 130


RESULT 21
AAB48377
ID   AAB48377 standard; Protein; 464 AA.
XX
AC   AAB48377;
XX
DT   20-APR-2001  (first entry)
XX
DE   Human SEC10 protein sequence (clone ID 1795045.0.77).
XX
KW   SECX; cytostatic; gynecological; gene therapy; screening assay; human;
KW   SEC10; chromosomal mapping; forensic biology; cell proliferation; cancer;
KW   cell differentiation; immune associated disorder; gestational disease.
XX
OS   Homo sapiens.
XX
PN   WO200078802-A2.
XX
PD   28-DEC-2000.
XX
PF   23-JUN-2000; 2000WO-US17328.
XX
PR   23-JUN-1999;   99US-0140584.
PR   20-JUL-1999;   99US-0144722.
PR   16-SEP-1999;   99US-0154520.
PR   22-JUN-2000; 2000US-0604286.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Shimkets RA,  Fernandes E,  Vernet C,  Yang M,  Boldog FL;
PI   Herrmann JL;
XX
DR   WPI; 2001-071385/08.
DR   N-PSDB; AAC84891.
XX
PT   Polynucleotides encoding SECX proteins useful for treating disease
PT   characterized by an aberrant level of cell proliferation and/or
PT   differentiation like cancer or immune associated disorders -
XX
PS   Claim 1; Fig 10; 132pp; English.
XX
CC   The invention relates to human SECX polypeptides and polynucleotides
CC   encoding them. The SECX polypeptides can be expressed by standard
CC   recombinant methodology.  The SECX polypeptides are useful for treating
CC   or preventing a SECX-associated disorder. The invention is useful in
CC   screening assays; detection assays (e.g. chromosomal mapping, cell and
CC   tissue typing, forensic biology); predictive medicine (diagnostic assays,
CC   prognostic assays, monitoring clinical trials, and pharmocogenomics); and
CC   methods of treatment (e.g. therapeutic and prophylactic), especially
CC   disorders characterized by aberrant cell proliferation and/ or
CC   differentiation like cancer or immune associated disorders or gestational
CC   disease. The present sequence represents a SEC10 protein.
XX
SQ   Sequence   464 AA;

  Query Match             1.5%;  Score 15;  DB 22;  Length 464;
  Best Local Similarity   100.0%;  Pred. No. 1.7e-06;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    268 GVAYTSECFPCKPGT 282
          |||||||||||||||
Db    169 GVAYTSECFPCKPGT 183


RESULT 22
AAB70255
ID   AAB70255 standard; protein; 963 AA.
XX
AC   AAB70255;
XX
DT   10-MAY-2001  (first entry)
```

```
XX
DE   TR16-short receptor protein.
XX
KW   TR16 recptor; tumour necrosis factor receptor superfamily;
KW   apoptosis; inflammatory; cancer; immune; neurodegenerative.
XX
OS   Unidentified.
XX
PN   WO200112671-A1.
XX
PD   22-FEB-2001.
XX
PF   10-AUG-2000; 2000WO-US21885.
XX
PR   12-AUG-1999;   99US-0148348.
PR   13-AUG-1999;   99US-0148683.
PR   13-AUG-1999;   99US-0148870.
PR   16-AUG-1999;   99US-0148758.
PR   17-AUG-1999;   99US-0149181.
PR   18-AUG-1999;   99US-0149453.
PR   19-AUG-1999;   99US-0149498.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Young PE,  Baker KP;
XX
DR   WPI; 2001-138754/14.
XX
PT   New nucleic acid molecule encoding a TR16 tumor necrosis factor
PT   receptor polypeptide, useful for the diagnosis and treatment of cancer,
PT   autoimmune disorders and cardiovascular diseases -
XX
PS   Claim 1; Fig 1; 286pp; English.
XX
CC   The present invention relates to a TR16 receptor (tumour necrosis
CC   factor receptor superfamily). The invention is useful treating
CC   diseases and disorders associated with the inhibited or increased
CC   apoptosis. In particular inflammatory diseases, cancers, immune and
CC   neurodegenerative disorders may be treated.
XX
SQ   Sequence   963 AA;

  Query Match             1.5%;  Score 15;  DB 22;  Length 963;
  Best Local Similarity   100.0%;  Pred. No. 3.3e-06;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     268 GVAYTSECFPCKPGT 282
           |||||||||||||||
Db     283 GVAYTSECFPCKPGT 297


RESULT 23
ABB39681
ID   ABB39681 standard; Peptide; 50 AA.
XX
AC   ABB39681;
XX
DT   04-FEB-2002  (first entry)
XX
DE   Peptide #7187 encoded by human foetal liver single exon probe.
XX
KW   Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS   Homo sapiens.
XX
PN   WO200157277-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00669.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human fetal liver -
XX
PS   Claim 27; SEQ ID NO 32316; 639pp + sequence listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for
CC   measuring human gene expression in a sample derived from human foetal
CC   liver. The single exon nucleic acid probes may be used for predicting,
CC   measuring and displaying gene expression in samples derived from human
CC   fetal liver. The present sequence is a peptide encoded by a single exon
CC   nucleic acid probe of the invention.
CC   Note: The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   50 AA;

  Query Match             1.4%;  Score 14;  DB 22;  Length 50;
  Best Local Similarity   100.0%;  Pred. No. 2.6e-06;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     955 LPAADSCAIMEGED 968
           ||||||||||||||
Db      19 LPAADSCAIMEGED 32


RESULT 24
ABB24346
ID   ABB24346 standard; Protein; 50 AA.
XX
AC   ABB24346;
XX
DT   23-JAN-2002  (first entry)
XX
DE   Protein #6345 encoded by probe for measuring heart cell gene expression.
XX
KW   Human; gene expression; heart; microarray; vascular system;
KW   cardiovascular disease; hypertension; cardiac arrhythmia;
KW   congenital heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157274-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00666.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488899/53.
```

XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT hearts -
XX
PS Claim 15; SEQ ID No 26116; 530pp; English.
XX
CC The present invention relates to single exon nucleic acid probes for
CC measuring human gene expression in a sample derived from human heart (see
CC ABA21535-ABA41305). The present sequence is a protein encoded by one such
CC probe. The probes may be used for predicting, measuring and displaying
CC gene expression in samples derived from the human heart via microarrays.
CC By measuring gene expression, the probes are useful for predicting,
CC diagnosing, grading, staging, monitoring and prognosing diseases of the
CC human heart and vascular system e.g. cardiovascular disease,
CC hypertension, cardiac arrhythmias and congenital heart disease.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 50 AA;

Query Match 1.4%; Score 14; DB 22; Length 50;
Best Local Similarity 100.0%; Pred. No. 2.6e-06;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 955 LPAADSCAIMEGED 968
||||||||||||||
Db 19 LPAADSCAIMEGED 32

RESULT 25
AAM60397
ID AAM60397 standard; Protein; 50 AA.
XX
AC AAM60397;
XX
DT 05-NOV-2001 (first entry)
XX
DE Human brain expressed single exon probe encoded protein SEQ ID NO: 32502.
XX
KW Human; brain expressed exon; gene expression analysis; probe;
KW microarray; Alzheimer's disease; multiple sclerosis; schizophrenia;
KW epilepsy; cancer.
XX
OS Homo sapiens.
XX
PN WO200157275-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00667.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483446/52.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT brains -
XX
PS Example 4; SEQ ID NO: 32502; 650pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC brain. They can be used to measure gene expression in brain cell samples,
CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancers. The present sequence is a protein encoded by one of
CC the probes of the invention.
XX
SQ Sequence 50 AA;

Query Match 1.4%; Score 14; DB 22; Length 50;
Best Local Similarity 100.0%; Pred. No. 2.6e-06;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 955 LPAADSCAIMEGED 968
||||||||||||||
Db 19 LPAADSCAIMEGED 32

RESULT 26
AAM73033
ID AAM73033 standard; Protein; 50 AA.
XX
AC AAM73033;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed probe encoded protein SEQ ID NO: 33339.
XX
KW Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS Homo sapiens.
XX
PN WO200157276-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00668.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488900/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for
PT analyzing gene expression in human bone marrow -
XX
PS Example 4; SEQ ID NO: 33339; 658pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC bone marrow. They can be used to measure gene expression in bone marrow
CC samples, which may enable the improved diagnosis and treatment of cancers
CC such as lymphoma, leukaemia and myeloma. The present sequence is a
CC protein encoded by one of the probes of the invention.
XX
SQ Sequence 50 AA;

Query Match 1.4%; Score 14; DB 22; Length 50;
Best Local Similarity 100.0%; Pred. No. 2.6e-06;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 955 LPAADSCAIMEGED 968
||||||||||||||
Db 19 LPAADSCAIMEGED 32

```
RESULT 27
AAM19811
ID   AAM19811 standard; Protein; 50 AA.
XX
AC   AAM19811;
XX
DT   12-OCT-2001  (first entry)
XX
DE   Peptide #6245 encoded by probe for measuring cervical gene expression.
XX
KW   Probe; human; microarray; gene expression; cervical epithelial cell;
KW   cervical cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157278-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00670.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488901/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human cervical epithelial cells -
XX
PS   Claim 27; SEQ ID No 24637; 487pp; English.
XX
CC   The present invention relates to human single exon nucleic acid probes
CC   (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC   by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC   can be used to produce a single exon microarray, which can be used for
CC   measuring human gene expression in a sample derived from human cervical
CC   epithelial cells. By measuring gene expression, the probes are therefore
CC   useful in grading and/or staging of diseases of the cervix, notably
CC   cervical cancer.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   50 AA;

  Query Match             1.4%;  Score 14;  DB 22;  Length 50;
  Best Local Similarity   100.0%;  Pred. No. 2.6e-06;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     955 LPAADSCAIMEGED 968
           ||||||||||||||
Db      19 LPAADSCAIMEGED 32


RESULT 28
AAM33257
ID   AAM33257 standard; Protein; 50 AA.
XX
AC   AAM33257;
XX
DT   17-OCT-2001  (first entry)
XX
DE   Peptide #7294 encoded by probe for measuring placental gene expression.
XX
KW   Probe; microarray; human; placenta; antenatal diagnosis;
KW   genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200157272-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00663.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488897/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human placenta -
XX
PS   Claim 27; SEQ ID No 33526; 654pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes (SENP:
CC   see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for producing a microarray for
CC   predicting, measuring and displaying gene expression in samples derived
CC   from human placenta. The probes are useful for antenatal diagnosis of
CC   human genetic disorders.
XX
SQ   Sequence   50 AA;

  Query Match             1.4%;  Score 14;  DB 22;  Length 50;
  Best Local Similarity   100.0%;  Pred. No. 2.6e-06;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     955 LPAADSCAIMEGED 968
           ||||||||||||||
Db      19 LPAADSCAIMEGED 32


RESULT 29
ABG42877
ID   ABG42877 standard; Peptide; 50 AA.
XX
AC   ABG42877;
XX
DT   19-AUG-2002  (first entry)
XX
DE   Human peptide encoded by genome-derived single exon probe SEQ ID 32542.
XX
KW   Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW   chronic obstructive pulmonary disease; interstitial lung disease;
KW   familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW   tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW   Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW   pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW   pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW   primary ciliary dyskinesis; pulmonary hypertension;
KW   hyaline membrane disease.
XX
OS   Homo sapiens.
XX
PN   WO200186003-A2.
```

XX
PD 15-NOV-2001.
XX
PF 30-JAN-2001; 2001WO-US00665.
XX
PR 04-FEB-2000; 2000US-180312P.
PR 26-MAY-2000; 2000US-207456P.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2002-114183/15.
XX
PT Spatially-addressable set of single exon nucleic acid probes, used to
PT measure gene expression in human lung samples -
XX
PS Claim 27; SEQ ID No 32542; 634pp; English.
XX
CC The invention relates to a spatially-addressable set of single exon
CC nucleic acid probes for measuring gene expression in a sample derived
CC from human lung comprising single exon nucleic acid probes having one of
CC 12614 nucleic acid sequences mentioned in the specification, or their
CC complements or the 12387 open reading frames derived from the 12614
CC probes. Also included are a microarray comprising the novel set of
CC probes; the novel set of probes which hybridise at high stringency to a
CC nucleic acid expressed in the human lung; measuring gene expression in a
CC sample derived from human lung, comprising (a) contacting the array with
CC a collection of detectably labeled nucleic acids derived from human lung
CC mRNA, and (b) measuring the label detectably bound to each probe of
CC the array; identifying exons in a eukaryotic genome, comprising
CC (a) algorithmically predicting at least one exon from genomic sequences
CC of the eukaryote; and (b) detecting specific hybridisation of detectably
CC labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC having a fragment identical to the predicted exon, the probe is included
CC in the above mentioned microarray; assigning exons to a single gene,
CC comprising (a) identifying exons from genomic sequence by the method
CC above and (b) measuring the expression of each of the exons in several
CC tissues and/or cell types using hybridisation to a single exon
CC microarrays having a probe with the exon, where a common pattern of
CC expression of the exons in the tissues and/or cell types indicates that
CC the exons should be assigned to a single gene; a peptide comprising one
CC of 12011 sequences, mentioned in the specification, or encoded by the
CC probes/open reading frames (ORF). The probes are used for gene
CC expression analysis, and for identifying exons in a gene, particularly
CC using human lung derived mRNA and for the study of lung diseases
CC such as asthma, lung cancer, chronic obstructive pulmonary disease
CC (COPD), interstitial lung disease (ILD), familial idiopathic pulmonary
CC fibrosis, neurofibromatosis, tuberous sclerosis, Gaucher's disease,
CC Niemann-Pick disease, Hermansky-Pudlak syndrome, sarcoidosis, pulmonary
CC haemosiderosis, pulmonary histiocytosis, lymphangioleiomyomtosis,
CC pulmonary alveolar proteinosis, Karagener syndrome, fibrocystic
CC pulmonary dysplasia, primary ciliary dyskinesis, pulmonary hypertension
CC and hyaline membrane disease. The present sequence is a peptide/protein
CC encoded by a single exon probe of the invention.
CC Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic
CC format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 50 AA;

Query Match 1.4%; Score 14; DB 23; Length 50;
Best Local Similarity 100.0%; Pred. No. 2.6e-06;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 955 LPAADSCAIMEGED 968
|||||||||||||

Db 19 LPAADSCAIMEGED 32

RESULT 30
AAU21345
ID AAU21345 standard; Protein; 71 AA.
XX
AC AAU21345;
XX
DT 18-DEC-2001 (first entry)
XX
DE Human novel foetal antigen, SEQ ID NO 1589.
XX
KW Human; foetal tissue antigen; antiinflammatory; neuroprotective;
KW immunomodulator; cardiovascular; cytostatic; nephrothropic;
KW cardiovascular; autoimmune disease; rheumatoid arthritis;
KW hyperproliferative disorder; breast neoplasm; cancer;
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW cerebral ischaemia; angiogenesis; nervous system disorder;
KW Alzheimer's disease; infection; ocular disorder; corneal infection;
KW wound healing; epithelial cell proliferation; food additive.
XX
OS Homo sapiens.
XX
PN WO200155312-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01321.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.

PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-488782/53.
DR N-PSDB; AAS34165.
XX
PT New polynucleotides and polypeptides for diagnosing, treating,
PT preventing or prognosing e.g. diseases or disorders of the nervous,
PT musculoskeletal, excretory, gastrointestinal, reproductive, and
PT respiratory systems -
XX
PS Claim 11; SEQ ID No 1589; 642pp; English.
XX
CC The invention relates to novel nucleic acids encoding novel human foetal
CC antigens. The nucleic acids and proteins are used to prevent, treat (e.g.
CC by gene therapy) or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They
CC are also used in diagnosing a pathological condition or susceptibility
CC to a pathological condition. The antibodies to the antigens can also
CC be used in alleviating symptoms associated with the disorders and in
CC diagnostic immunoassays e.g. radioimmunoassays or enzyme linked
CC immunosorbent assays (ELISA). Disorders which are diagnosed or treated
CC include autoimmune diseases e.g. rheumatoid arthritis,
CC hyperproliferative disorders e.g. neoplasms of the breast or liver,
CC cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders
CC e.g. cerebral ischaemia, angiogenesis, nervous system disorders e.g.
CC Alzheimer's disease, infections caused by bacteria, viruses and fungi
CC and ocular disorders e.g. corneal infection. The polypeptides can also
CC be used to aid wound healing and epithelial cell proliferation, to
CC prevent skin aging due to sunburn, to maintain organs before
CC transplantation, for supporting cell culture of primary tissues, to
CC regenerate tissues and in chemotaxis. The polypeptides can also be used
CC as a food additive or preservative to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, cofactors and other nutritional components. Numerous
CC examples of diseases and disorders treated by the nucleic acids and
CC proteins are given in the specification. The present sequence

Query Match 1.4%; Score 14; DB 22; Length 71;
Best Local Similarity 100.0%; Pred. No. 3.6e-06;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 955 LPAADSCAIMEGED 968
||||||||||||||
Db 16 LPAADSCAIMEGED 29

RESULT 31
AAB70285
ID AAB70285 standard; peptide; 78 AA.
XX

```
AC   AAB70285;
XX
DT   10-MAY-2001  (first entry)
XX
DE   Peptide #29.
XX
KW   TR16 recptor; tumour necrosis factor receptor superfamily;
KW   apoptosis; inflammatory; cancer; immune; neurodegenerative.
XX
OS   Unidentified.
XX
PN   WO200112671-A1.
XX
PD   22-FEB-2001.
XX
PF   10-AUG-2000; 2000WO-US21885.
XX
PR   12-AUG-1999;   99US-0148348.
PR   13-AUG-1999;   99US-0148683.
PR   13-AUG-1999;   99US-0148870.
PR   16-AUG-1999;   99US-0148758.
PR   17-AUG-1999;   99US-0149181.
PR   18-AUG-1999;   99US-0149453.
PR   19-AUG-1999;   99US-0149498.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Young PE,  Baker KP;
XX
DR   WPI; 2001-138754/14.
XX
PT   New nucleic acid molecule encoding a TR16 tumor necrosis factor
PT   receptor polypeptide, useful for the diagnosis and treatment of cancer,
PT   autoimmune disorders and cardiovascular diseases -
XX
PS   Disclosure; Page 81; 286pp; English.
XX
CC   The present invention relates to a TR16 receptor (tumour necrosis
CC   factor receptor superfamily). The invention is useful treating
CC   diseases and disorders associated with the inhibited or increased
CC   apoptosis. In particular inflammatory diseases, cancers, immune and
CC   neurodegenerative disorders may be treated.
XX
SQ   Sequence   78 AA;

  Query Match             1.4%;  Score 14;  DB 22;  Length 78;
  Best Local Similarity   100.0%;  Pred. No. 3.9e-06;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    933 KNQKLEYKYSKLVM 946
          ||||||||||||||
Db      1 KNQKLEYKYSKLVM 14


RESULT 32
AAB27114
ID   AAB27114 standard; Protein; 10 AA.
XX
AC   AAB27114;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 40.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases  -
XX
PS   Example 7; Page 62; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   10 AA;

  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    866 AIVSSCVAGI 875
          ||||||||||
Db      1 AIVSSCVAGI 10


RESULT 33
AAB27115
ID   AAB27115 standard; Protein; 10 AA.
XX
AC   AAB27115;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 41.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases  -
XX
PS   Example 7; Page 62; 68pp; English.
XX
```

```
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   10 AA;

  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    852 SAAACPLCSV 861
          ||||||||||
Db      1 SAAACPLCSV 10


RESULT 34
AAB27116
ID   AAB27116 standard; Protein; 10 AA.
XX
AC   AAB27116;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 42.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases  -
XX
PS   Example 7; Page 62; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   10 AA;

  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    786 HLESLGIPDV 795
          ||||||||||
Db      1 HLESLGIPDV 10


RESULT 35
AAB27117
ID   AAB27117 standard; Protein; 10 AA.
XX
AC   AAB27117;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 43.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases  -
XX
PS   Example 7; Page 62; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   10 AA;

  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    571 KIYSINVTNV 580
          ||||||||||
Db      1 KIYSINVTNV 10


RESULT 36
AAB27118
ID   AAB27118 standard; Protein; 10 AA.
XX
AC   AAB27118;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 44.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
```

XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 62; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.01;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 761 SLADRLIGVT 770
||||||||||
Db 1 SLADRLIGVT 10

RESULT 37
AAB27119
ID AAB27119 standard; Protein; 10 AA.
XX
AC AAB27119;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 45.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 62; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.01;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 626 ILKAHQPYGV 635
||||||||||
Db 1 ILKAHQPYGV 10

RESULT 38
AAB27120
ID AAB27120 standard; Protein; 10 AA.
XX
AC AAB27120;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 46.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 63; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;

```
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    485 VMADTENKEV 494
          ||||||||||
Db      1 VMADTENKEV 10


RESULT 39
AAB27121
ID   AAB27121 standard; Protein; 10 AA.
XX
AC   AAB27121;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 47.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases  -
XX
PS   Example 7; Page 63; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   10 AA;

  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     29 LLWAGTAFQV 38
          ||||||||||
Db      1 LLWAGTAFQV 10


RESULT 40
AAB27122
ID   AAB27122 standard; Protein; 10 AA.
XX
AC   AAB27122;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 48.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases  -
XX
PS   Example 7; Page 63; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   10 AA;

  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    916 GTCTAILLTV 925
          ||||||||||
Db      1 GTCTAILLTV 10


RESULT 41
AAB27123
ID   AAB27123 standard; Protein; 10 AA.
XX
AC   AAB27123;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 49.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
```

PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 63; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.01;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 778 ITSPAELFHL 787
||||||||||
Db 1 ITSPAELFHL 10

RESULT 42
AAB27124
ID AAB27124 standard; Protein; 10 AA.
XX
AC AAB27124;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 50.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 63; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.01;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 766 LIGVTTDMTL 775
||||||||||
Db 1 LIGVTTDMTL 10

RESULT 43
AAB27125
ID AAB27125 standard; Protein; 10 AA.
XX
AC AAB27125;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 51.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 63; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.01;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 428 TLPTNMETTV 437
||||||||||
Db 1 TLPTNMETTV 10

RESULT 44
AAB27126
ID AAB27126 standard; Protein; 10 AA.
XX

```
AC   AAB27126;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 52.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases  -
XX
PS   Example 7; Page 63; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   10 AA;

  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     350 LMYKWAKPKI 359
           ||||||||||
Db       1 LMYKWAKPKI 10


RESULT 45
AAB27128
ID   AAB27128 standard; Protein; 10 AA.
XX
AC   AAB27128;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 54.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases  -
XX
PS   Example 7; Page 64; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   10 AA;

  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     692 GLKYFHHFTL 701
           ||||||||||
Db       1 GLKYFHHFTL 10


RESULT 46
AAB27129
ID   AAB27129 standard; Protein; 10 AA.
XX
AC   AAB27129;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 55.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases  -
XX
PS   Example 7; Page 64; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
```

```
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   10 AA;

  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    644 GTKNNKIHSL 653
          ||||||||||
Db      1 GTKNNKIHSL 10


RESULT 47
AAB27130
ID   AAB27130 standard; Protein; 10 AA.
XX
AC   AAB27130;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 56.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases  -
XX
PS   Example 7; Page 64; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   10 AA;

  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    465 SDNDFMILTL 474
          ||||||||||
Db      1 SDNDFMILTL 10


RESULT 48
AAB27131
ID   AAB27131 standard; Protein; 10 AA.
XX
AC   AAB27131;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 57.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases  -
XX
PS   Example 7; Page 64; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   10 AA;

  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    260 LVRNIAITGV 269
          ||||||||||
Db      1 LVRNIAITGV 10


RESULT 49
AAB27132
ID   AAB27132 standard; Protein; 10 AA.
XX
AC   AAB27132;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 58.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
```

```
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases -
XX
PS   Example 7; Page 64; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   10 AA;

  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     77 GLCTSLPDPV 86
          ||||||||||
Db      1 GLCTSLPDPV 10


RESULT 50
AAB27133
ID   AAB27133 standard; Protein; 10 AA.
XX
AC   AAB27133;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 59.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases -
XX
PS   Example 7; Page 64; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   10 AA;

  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    949 TLKDCDLPAA 958
          ||||||||||
Db      1 TLKDCDLPAA 10


RESULT 51
AAB27134
ID   AAB27134 standard; Protein; 10 AA.
XX
AC   AAB27134;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 60.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases -
XX
PS   Example 7; Page 65; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   10 AA;

  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy     795 VIFFYRSNDV 804
           ||||||||||
Db       1 VIFFYRSNDV 10
```

RESULT 52
AAB27135
ID AAB27135 standard; Protein; 10 AA.
XX
AC AAB27135;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 61.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 65; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 10 AA;

```
  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     733 SITAYVCQAV 742
           ||||||||||
Db       1 SITAYVCQAV 10
```

RESULT 53
AAB27136
ID AAB27136 standard; Protein; 10 AA.
XX
AC AAB27136;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 62.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 65; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 10 AA;

```
  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     712 SVCTDNVTDL 721
           ||||||||||
Db       1 SVCTDNVTDL 10
```

RESULT 54
AAB27137
ID AAB27137 standard; Protein; 10 AA.
XX
AC AAB27137;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 63.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX

```
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases -
XX
PS   Example 7; Page 65; 68pp; English.
XX
CC   The present sequence comprises an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   10 AA;

  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     702 SLCGNQGRKM 711
           ||||||||||
Db       1 SLCGNQGRKM 10


RESULT 55
AAB27138
ID   AAB27138 standard; Protein; 10 AA.
XX
AC   AAB27138;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 64.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases -
XX
PS   Example 7; Page 65; 68pp; English.
XX
CC   The present sequence comprises an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   10 AA;

  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     432 NMETTVLSGI 441
           ||||||||||
Db       1 NMETTVLSGI 10


RESULT 56
AAB27139
ID   AAB27139 standard; Protein; 10 AA.
XX
AC   AAB27139;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 65.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases -
XX
PS   Example 7; Page 65; 68pp; English.
XX
CC   The present sequence comprises an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   10 AA;

  Query Match             1.0%;  Score 10;  DB 21;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.01;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     263 NIAITGVAYT 272
           ||||||||||
Db       1 NIAITGVAYT 10


RESULT 57
AAB27140
ID   AAB27140 standard; Protein; 10 AA.
XX
AC   AAB27140;
XX
```

DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 66.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 65; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.01;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 121 GIRFDEWDEL 130
||||||||||
Db 1 GIRFDEWDEL 10

RESULT 58
AAB27141
ID AAB27141 standard; Protein; 10 AA.
XX
AC AAB27141;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 67.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 66; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.01;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 846 FHFLWESAAA 855
||||||||||
Db 1 FHFLWESAAA 10

RESULT 59
AAB26181
ID AAB26181 standard; Protein; 9 AA.
XX
AC AAB26181;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 4.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 57; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the

```
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   9 AA;

  Query Match             0.9%;  Score 9;  DB 21;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 7.8e+05;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     24 RLWRLLLWA 32
          |||||||||
Db      1 RLWRLLLWA 9


RESULT 60
AAB26182
ID   AAB26182 standard; Protein; 9 AA.
XX
AC   AAB26182;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 5.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases  -
XX
PS   Example 7; Page 57; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   9 AA;

  Query Match             0.9%;  Score 9;  DB 21;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 7.8e+05;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    761 SLADRLIGV 769
          |||||||||
Db      1 SLADRLIGV 9


RESULT 61
AAB26183
ID   AAB26183 standard; Protein; 9 AA.
XX
AC   AAB26183;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 7.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases  -
XX
PS   Example 7; Page 57; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   9 AA;

  Query Match             0.9%;  Score 9;  DB 21;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 7.8e+05;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    893 SLPEQRVTI 901
          |||||||||
Db      1 SLPEQRVTI 9


RESULT 62
AAB26184
ID   AAB26184 standard; Protein; 9 AA.
XX
AC   AAB26184;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 8.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
```

XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 57; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 886 KLCSGGISL 894
|||||||||
Db 1 KLCSGGISL 9

RESULT 63
AAB26185
ID AAB26185 standard; Protein; 9 AA.
XX
AC AAB26185;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 9.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 57; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 853 AAACPLCSV 861
|||||||||
Db 1 AAACPLCSV 9

RESULT 64
AAB26186
ID AAB26186 standard; Protein; 9 AA.
XX
AC AAB26186;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 10.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 57; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 674 SALANTVTL 682

```
          |||||||||
Db        1 SALANTVTL 9


RESULT 65
AAB26187
ID   AAB26187 standard; Protein; 9 AA.
XX
AC   AAB26187;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 11.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases  -
XX
PS   Example 7; Page 58; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   9 AA;

  Query Match             0.9%;  Score 9;  DB 21;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 7.8e+05;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     499 FVFETLCSV 507
           |||||||||
Db       1 FVFETLCSV 9


RESULT 66
AAB26188
ID   AAB26188 standard; Protein; 9 AA.
XX
AC   AAB26188;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 12.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases  -
XX
PS   Example 7; Page 58; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   9 AA;

  Query Match             0.9%;  Score 9;  DB 21;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 7.8e+05;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     129 ELPHGFASL 137
           |||||||||
Db       1 ELPHGFASL 9


RESULT 67
AAB26190
ID   AAB26190 standard; Protein; 9 AA.
XX
AC   AAB26190;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 14.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
```

PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 58; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 936 KLEYKYSKL 944
|||||||||
Db 1 KLEYKYSKL 9

RESULT 68
AAB26191
ID AAB26191 standard; Protein; 9 AA.
XX
AC AAB26191;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 15.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 58; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 903 KTIDFWLKV 911
|||||||||
Db 1 KTIDFWLKV 9

RESULT 69
AAB26192
ID AAB26192 standard; Protein; 9 AA.
XX
AC AAB26192;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 16.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 58; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 860 SVADYHAIV 868
|||||||||
Db 1 SVADYHAIV 9

RESULT 70
AAB26193
ID AAB26193 standard; Protein; 9 AA.
XX
AC AAB26193;
XX
DT 12-FEB-2001 (first entry)
XX

DE Human CASB619 protein epitope SEQ ID NO: 17.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 58; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 830 LLLPGTCSD 838
||||||||| |
Db 1 LLLPGTCSD 9

RESULT 71
AAB26194
ID AAB26194 standard; Protein; 9 AA.
XX
AC AAB26194;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 18.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 59; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 675 ALANTVTLA 683
||||||||| |
Db 1 ALANTVTLA 9

RESULT 72
AAB26195
ID AAB26195 standard; Protein; 9 AA.
XX
AC AAB26195;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 19.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 59; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines

```
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   9 AA;

  Query Match             0.9%;  Score 9;  DB 21;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 7.8e+05;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     503 TLCSVNCEL 511
           |||||||||
Db       1 TLCSVNCEL 9


RESULT 73
AAB26196
ID   AAB26196 standard; Protein; 9 AA.
XX
AC   AAB26196;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 20.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases -
XX
PS   Example 7; Page 59; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   9 AA;

  Query Match             0.9%;  Score 9;  DB 21;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 7.8e+05;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     169 NTDECTATL 177
           |||||||||
Db       1 NTDECTATL 9


RESULT 74
AAB26197
ID   AAB26197 standard; Protein; 9 AA.
XX
AC   AAB26197;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 21.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases -
XX
PS   Example 7; Page 59; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   9 AA;

  Query Match             0.9%;  Score 9;  DB 21;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 7.8e+05;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      81 SLPDPVKGT 89
           |||||||||
Db       1 SLPDPVKGT 9


RESULT 75
AAB26199
ID   AAB26199 standard; Protein; 9 AA.
XX
AC   AAB26199;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 23.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
```

XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 59; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 918 CTAILLTVL 926
||||||||| |
Db 1 CTAILLTVL 9

RESULT 76
AAB26200
ID AAB26200 standard; Protein; 9 AA.
XX
AC AAB26200;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 24.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 59; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 867 IVSSCVAGI 875
||||||||| |
Db 1 IVSSCVAGI 9

RESULT 77
AAB26201
ID AAB26201 standard; Protein; 9 AA.
XX
AC AAB26201;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 25.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 60; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 710 KMSVCTDNV 718
||||||||| |
Db 1 KMSVCTDNV 9

RESULT 78
AAB26202
ID AAB26202 standard; Protein; 9 AA.
XX
AC AAB26202;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 26.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 60; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 259 VLVRNIAIT 267
        |||||||||
Db 1 VLVRNIAIT 9

RESULT 79
AAB27101
ID AAB27101 standard; Protein; 9 AA.
XX
AC AAB27101;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 27.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 60; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 234 ELNRGNNVL 242
        |||||||||
Db 1 ELNRGNNVL 9

RESULT 80
AAB27102
ID AAB27102 standard; Protein; 9 AA.
XX
AC AAB27102;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 28.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly

PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 60; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 175 ATLMYAVNL 183
||||||||| |
Db 1 ATLMYAVNL 9

RESULT 81
AAB27103
ID AAB27103 standard; Protein; 9 AA.
XX
AC AAB27103;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 29.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 60; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 70 VAVPHTPGL 78
||||||||| |
Db 1 VAVPHTPGL 9

RESULT 82
AAB27104
ID AAB27104 standard; Protein; 9 AA.
XX
AC AAB27104;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 30.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 60; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 24 RLWRLLLWA 32
||||||||| |
Db 1 RLWRLLLWA 9

RESULT 83
AAB27105
ID AAB27105 standard; Protein; 9 AA.
XX
AC AAB27105;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 31.
XX

KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 60; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 914 SAGTCTAIL 922
||||||||| |
Db 1 SAGTCTAIL 9

RESULT 84
AAB27106
ID AAB27106 standard; Protein; 9 AA.
XX
AC AAB27106;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 32.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 61; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 891 GISLPEQRV 899
||||||||| |
Db 1 GISLPEQRV 9

RESULT 85
AAB27107
ID AAB27107 standard; Protein; 9 AA.
XX
AC AAB27107;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 33.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 61; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.

```
XX
SQ   Sequence   9 AA;

  Query Match             0.9%;  Score 9;  DB 21;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 7.8e+05;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     824 KTVPGSLLL 832
           |||||||||
Db       1 KTVPGSLLL 9


RESULT 86
AAB27108
ID   AAB27108 standard; Protein; 9 AA.
XX
AC   AAB27108;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 34.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases  -
XX
PS   Example 7; Page 61; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   9 AA;

  Query Match             0.9%;  Score 9;  DB 21;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 7.8e+05;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     765 RLIGVTTDM 773
           |||||||||
Db       1 RLIGVTTDM 9


RESULT 87
AAB27109
ID   AAB27109 standard; Protein; 9 AA.
XX
AC   AAB27109;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 35.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases  -
XX
PS   Example 7; Page 61; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   9 AA;

  Query Match             0.9%;  Score 9;  DB 21;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 7.8e+05;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     681 TLAGGPSFT 689
           |||||||||
Db       1 TLAGGPSFT 9


RESULT 88
AAB27110
ID   AAB27110 standard; Protein; 9 AA.
XX
AC   AAB27110;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 36.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
```

PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 61; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 539 YIIEENTTT 547
||||||||| |
Db 1 YIIEENTTT 9

RESULT 89
AAB27111
ID AAB27111 standard; Protein; 9 AA.
XX
AC AAB27111;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 37.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 61; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 264 IAITGVAYT 272
||||||||| |
Db 1 IAITGVAYT 9

RESULT 90
AAB27112
ID AAB27112 standard; Protein; 9 AA.
XX
AC AAB27112;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 38.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 61; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX
SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 38 VTQGTGPEL 46
||||||||| |
Db 1 VTQGTGPEL 9

```
RESULT 91
AAB27142
ID   AAB27142 standard; Protein; 9 AA.
XX
AC   AAB27142;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human CASB619 protein epitope SEQ ID NO: 68.
XX
KW   Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW   epitope.
XX
OS   Homo sapiens.
XX
PN   WO200058460-A2.
XX
PD   05-OCT-2000.
XX
PF   20-MAR-2000; 2000WO-EP02478.
XX
PR   26-MAR-1999;   99GB-0007113.
PR   25-SEP-1999;   99GB-0022858.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals De Bassols YC;
XX
DR   WPI; 2000-664923/64.
XX
PT   Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT   prophylactic and therapeutic treatment of, cancers, particularly
PT   ovarian and colon carcinoma, and autoimmune diseases -
XX
PS   Example 7; Page 66; 68pp; English.
XX
CC   The present sequence comprises  an epitope derived from the human CASB619
CC   protein sequence. This protein is thought to be specifically or
CC   over-expressed in tumour cells, and so can be used as a target for
CC   antigen-specific immune responses which can cause destruction of the
CC   tumour cell. In addition, the protein and gene can be used in cancer
CC   diagnosis, in the treatment of autoimmune diseases and in vaccines
CC   against cancer and autoimmune disease. The present sequence can be used
CC   as an immunogen.
XX
SQ   Sequence   9 AA;

  Query Match             0.9%;  Score 9;  DB 21;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 7.8e+05;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     848 FLWESAAAC 856
           |||||||||
Db       1 FLWESAAAC 9


RESULT 92
ABB38903
ID   ABB38903 standard; Peptide; 32 AA.
XX
AC   ABB38903;
XX
DT   04-FEB-2002  (first entry)
XX
DE   Peptide #6409 encoded by human foetal liver single exon probe.
XX
KW   Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS   Homo sapiens.
XX
PN   WO200157277-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00669.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human fetal liver -
XX
PS   Claim 27; SEQ ID NO 31538; 639pp + sequence listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for
CC   measuring human gene expression in a sample derived from human foetal
CC   liver. The single exon nucleic acid probes may be used for predicting,
CC   measuring and displaying gene expression in samples derived from human
CC   fetal liver. The present sequence is a peptide encoded by a single exon
CC   nucleic acid probe of the invention.
CC   Note: The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   32 AA;

  Query Match             0.9%;  Score 9;  DB 22;  Length 32;
  Best Local Similarity   100.0%;  Pred. No. 0.33;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     964 MEGEDVEDD 972
           |||||||||
Db       1 MEGEDVEDD 9


RESULT 93
ABB23896
ID   ABB23896 standard; Protein; 32 AA.
XX
AC   ABB23896;
XX
DT   23-JAN-2002  (first entry)
XX
DE   Protein #5895 encoded by probe for measuring heart cell gene expression.
XX
KW   Human; gene expression; heart; microarray; vascular system;
KW   cardiovascular disease; hypertension; cardiac arrhythmia;
KW   congenital heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157274-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00666.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
```

PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488899/53.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT hearts -
XX
PS Claim 15; SEQ ID No 25666; 530pp; English.
XX
CC The present invention relates to single exon nucleic acid probes for
CC measuring human gene expression in a sample derived from human heart (see
CC ABA21535-ABA41305). The present sequence is a protein encoded by one such
CC probe. The probes may be used for predicting, measuring and displaying
CC gene expression in samples derived from the human heart via microarrays.
CC By measuring gene expression, the probes are useful for predicting,
CC diagnosing, grading, staging, monitoring and prognosing diseases of the
CC human heart and vascular system e.g. cardiovascular disease,
CC hypertension, cardiac arrhythmias and congenital heart disease.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 32 AA;

Query Match 0.9%; Score 9; DB 22; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.33;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 964 MEGEDVEDD 972
||||||||||
Db 1 MEGEDVEDD 9

RESULT 94
AAM59554
ID AAM59554 standard; Protein; 32 AA.
XX
AC AAM59554;
XX
DT 05-NOV-2001 (first entry)
XX
DE Human brain expressed single exon probe encoded protein SEQ ID NO: 31659.
XX
KW Human; brain expressed exon; gene expression analysis; probe;
KW microarray; Alzheimer's disease; multiple sclerosis; schizophrenia;
KW epilepsy; cancer.
XX
OS Homo sapiens.
XX
PN WO200157275-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00667.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483446/52.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT brains -
XX
PS Example 4; SEQ ID NO: 31659; 650pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC brain. They can be used to measure gene expression in brain cell samples,
CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancers. The present sequence is a protein encoded by one of
CC the probes of the invention.
XX
SQ Sequence 32 AA;

Query Match 0.9%; Score 9; DB 22; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.33;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 964 MEGEDVEDD 972
||||||||||
Db 1 MEGEDVEDD 9

RESULT 95
AAM72123
ID AAM72123 standard; Protein; 32 AA.
XX
AC AAM72123;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed probe encoded protein SEQ ID NO: 32429.
XX
KW Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS Homo sapiens.
XX
PN WO200157276-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00668.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488900/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for
PT analyzing gene expression in human bone marrow -
XX
PS Example 4; SEQ ID NO: 32429; 658pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC bone marrow. They can be used to measure gene expression in bone marrow
CC samples, which may enable the improved diagnosis and treatment of cancers
CC such as lymphoma, leukaemia and myeloma. The present sequence is a
CC protein encoded by one of the probes of the invention.
XX
SQ Sequence 32 AA;

Query Match 0.9%; Score 9; DB 22; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.33;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy     964 MEGEDVEDD 972
           |||||||||
Db       1 MEGEDVEDD 9
```

RESULT 96
AAM19447
ID AAM19447 standard; Protein; 32 AA.
XX
AC AAM19447;
XX
DT 12-OCT-2001 (first entry)
XX
DE Peptide #5881 encoded by probe for measuring cervical gene expression.
XX
KW Probe; human; microarray; gene expression; cervical epithelial cell;
KW cervical cancer.
XX
OS Homo sapiens.
XX
PN WO200157278-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00670.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488901/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for
PT analyzing gene expression in human cervical epithelial cells -
XX
PS Claim 27; SEQ ID No 24273; 487pp; English.
XX
CC The present invention relates to human single exon nucleic acid probes
CC (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC can be used to produce a single exon microarray, which can be used for
CC measuring human gene expression in a sample derived from human cervical
CC epithelial cells. By measuring gene expression, the probes are therefore
CC useful in grading and/or staging of diseases of the cervix, notably
CC cervical cancer.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 32 AA;

Query Match 0.9%; Score 9; DB 22; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.33;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy     964 MEGEDVEDD 972
           |||||||||
Db       1 MEGEDVEDD 9
```

RESULT 97
AAM32385
ID AAM32385 standard; Protein; 32 AA.
XX
AC AAM32385;
XX
DT 17-OCT-2001 (first entry)
XX
DE Peptide #6422 encoded by probe for measuring placental gene expression.
XX
KW Probe; microarray; human; placenta; antenatal diagnosis;
KW genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200157272-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00663.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488897/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for
PT analyzing gene expression in human placenta -
XX
PS Claim 27; SEQ ID No 32654; 654pp; English.
XX
CC The present invention relates to single exon nucleic acid probes (SENP:
CC see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC such probe. The probes are useful for producing a microarray for
CC predicting, measuring and displaying gene expression in samples derived
CC from human placenta. The probes are useful for antenatal diagnosis of
CC human genetic disorders.
XX
SQ Sequence 32 AA;

Query Match 0.9%; Score 9; DB 22; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.33;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy     964 MEGEDVEDD 972
           |||||||||
Db       1 MEGEDVEDD 9
```

RESULT 98
ABG41937
ID ABG41937 standard; Peptide; 32 AA.
XX
AC ABG41937;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human peptide encoded by genome-derived single exon probe SEQ ID 31602.
XX
KW Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW chronic obstructive pulmonary disease; interstitial lung disease;
KW familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW primary ciliary dyskinesis; pulmonary hypertension;

KW hyaline membrane disease.
XX
OS Homo sapiens.
XX
PN WO200186003-A2.
XX
PD 15-NOV-2001.
XX
PF 30-JAN-2001; 2001WO-US00665.
XX
PR 04-FEB-2000; 2000US-180312P.
PR 26-MAY-2000; 2000US-207456P.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2002-114183/15.
XX
PT Spatially-addressable set of single exon nucleic acid probes, used to
PT measure gene expression in human lung samples -
XX
PS Claim 27; SEQ ID No 31602; 634pp; English.
XX
CC The invention relates to a spatially-addressable set of single exon
CC nucleic acid probes for measuring gene expression in a sample derived
CC from human lung comprising single exon nucleic acid probes having one of
CC 12614 nucleic acid sequences mentioned in the specification, or their
CC complements or the 12387 open reading frames derived from the 12614
CC probes. Also included are a microarray comprising the novel set of
CC probes; the novel set of probes which hybridise at high stringency to a
CC nucleic acid expressed in the human lung; measuring gene expression in a
CC sample derived from human lung, comprising (a) contacting the array with
CC a collection of detectably labeled nucleic acids derived from human lung
CC mRNA, and (b) measuring the label detectably bound to each probe of
CC the array; identifying exons in a eukaryotic genome, comprising
CC (a) algorithmically predicting at least one exon from genomic sequences
CC of the eukaryote; and (b) detecting specific hybridisation of detectably
CC labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC having a fragment identical to the predicted exon, the probe is included
CC in the above mentioned microarray; assigning exons to a single gene,
CC comprising (a) identifying exons from genomic sequence by the method
CC above and (b) measuring the expression of each of the exons in several
CC tissues and/or cell types using hybridisation to a single exon
CC microarrays having a probe with the exon, where a common pattern of
CC expression of the exons in the tissues and/or cell types indicates that
CC the exons should be assigned to a single gene; a peptide comprising one
CC of 12011 sequences, mentioned in the specification, or encoded by the
CC probes/open reading frames (ORF). The probes are used for gene
CC expression analysis, and for identifying exons in a gene, particularly
CC using human lung derived mRNA and for the study of lung diseases
CC such as asthma, lung cancer, chronic obstructive pulmonary disease
CC (COPD), interstitial lung disease (ILD), familial idiopathic pulmonary
CC fibrosis, neurofibromatosis, tuberous sclerosis, Gaucher's disease,
CC Niemann-Pick disease, Hermansky-Pudlak syndrome, sarcoidosis, pulmonary
CC haemosiderosis, pulmonary histiocytosis, lymphangioleiomyomtosis,
CC pulmonary alveolar proteinosis, Karagener syndrome, fibrocystic
CC pulmonary dysplasia, primary ciliary dyskinesis, pulmonary hypertension
CC and hyaline membrane disease. The present sequence is a peptide/protein
CC encoded by a single exon probe of the invention.
CC Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic
CC format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 32 AA;

Query Match 0.9%; Score 9; DB 23; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.33;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 964 MEGEDVEDD 972
|||||||||
Db 1 MEGEDVEDD 9

RESULT 99
AAB57102
ID AAB57102 standard; Protein; 519 AA.
XX
AC AAB57102;
XX
DT 13-MAR-2001 (first entry)
XX
DE Human prostate cancer antigen protein sequence SEQ ID NO:1680.
XX
KW Human; prostate cancer; prostate cancer antigen; detection; diagnosis;
KW neuroprotective; cytostatic; cardioactive; immunomodulatory; muscular;
KW vulnerary; gastrointestinal; nephrotropic; antiinfective; gynaecological;
KW antibacterial; gene therapy; neural; immune; reproductive; renal;
KW gastrointestinal; pulmonary; cardiovascular; proliferative disorder;
KW wound; infectious disease.
XX
OS Homo sapiens.
XX
PN WO200055174-A1.
XX
PD 21-SEP-2000.
XX
PF 08-MAR-2000; 2000WO-US05988.
XX
PR 12-MAR-1999; 99US-0124270.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
PA (ROSE/) ROSEN C A.
XX
PI Rosen CA, Ruben SM;
XX
DR WPI; 2000-587513/55.
DR N-PSDB; AAF16305.
XX
PT Prostate cancer associated gene sequences, referred to as prostate
PT cancer antigens, useful for treatment, prevention, and diagnosis of
PT disorders such as prostate cancer -
XX
PS Claim 11; Page 2151-2153; 2338pp; English.
XX
CC AAF15566 to AAF16505 encode the human prostate cancer associated
CC proteins, called prostate cancer antigens, given in AAB56363 to AAB57302.
CC The prostate cancer antigens can have neuroprotective, cytostatic,
CC cardioactive, immunomodulatory, muscular, vulnerary, gastrointestinal,
CC nephrotropic, antiinfective, gynaecological and antibacterial activities,
CC and can be used in gene therapy. The prostate cancer antigen
CC polynucleotides may be used for detection of prostate cancer, chromosome
CC identification, as chromosome markers, and for numerous other diagnostic
CC or research purposes. The prostate cancer antigens may be used to treat
CC disorders such as neural, immune, muscular, reproductive,
CC gastrointestinal, pulmonary, cardiovascular, renal, and proliferative
CC disorders, wounds, and infectious diseases. AAF16506 to AAF16514 to
CC AAB57303 represent sequences used in the exemplification of the present
CC invention.
XX
SQ Sequence 519 AA;

Query Match 0.9%; Score 9; DB 21; Length 519;
Best Local Similarity 100.0%; Pred. No. 4;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 964 MEGEDVEDD 972
|||||||||
Db 41 MEGEDVEDD 49

RESULT 100
AAM78689
ID AAM78689 standard; Protein; 748 AA.
XX
AC AAM78689;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human protein SEQ ID NO 1351.
XX
KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW tissue growth factor; immunomodulatory; cancer; leukaemia;
KW nervous system disorder; arthritis; inflammation.
XX
OS Homo sapiens.
XX
PN WO200157190-A2.
XX
PD 09-AUG-2001.
XX
PF 05-FEB-2001; 2001WO-US04098.
XX
PR 03-FEB-2000; 2000US-0496914.
PR 27-APR-2000; 2000US-0560875.
PR 20-JUN-2000; 2000US-0598075.
PR 19-JUL-2000; 2000US-0620325.
PR 01-SEP-2000; 2000US-0654936.
PR 15-SEP-2000; 2000US-0663561.
PR 20-OCT-2000; 2000US-0693325.
PR 30-NOV-2000; 2000US-0728422.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y, Ma Y;
PI Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;
PI Xue AJ, Yang Y, Wejhrman T, Goodrich R;
XX
DR WPI; 2001-476283/51.
DR N-PSDB; AAK51822.
XX
PT Nucleic acids encoding polypeptides with cytokine-like activities,
PT useful in diagnosis and gene therapy -
XX
PS Claim 20; Page 3596-3597; 6221pp; English.
XX
CC The invention relates to polynucleotides (AAK51456-AAK53435) and the
CC encoded polypeptides (AAM78323-AAM80302) that exhibit activity elating to
CC cytokine, cell proliferation or cell differentiation or which may induce
CC production of other cytokines in other cell populations. The
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC peptide therapy. The polypeptides have various cytokine-like activities,
CC e.g. stem cell growth factor activity, haematopoiesis regulating
CC activity, tissue growth factor activity, immunomodulatory activity and
CC activin/inhibin activity and may be useful in the diagnosis and/or
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC inflammation.
CC Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3666
CC (AAM80020) are omitted as the relevant pages from the sequence listing
CC were missing at the time of publication.
XX
SQ Sequence 748 AA;

Query Match 0.9%; Score 9; DB 22; Length 748;
Best Local Similarity 100.0%; Pred. No. 5.6;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 964 MEGEDVEDD 972
||||||||| |
Db 8 MEGEDVEDD 16

Search completed: April 22, 2003, 15:33:47
Job time : 88 secs